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1.1. Acute kidney injury: an overview  
 
 Acute kidney injury (AKI), previously known as acute renal failure is characterised by 
a rapid decline in glomerular filtration rate (GFR) with retention of blood urea nitrogen and 
serum creatinine (SCr). Even though AKI is heterogeneous in its aetiology, as it may be 
caused by interstitial nephritis, glomerulonephritis, obstructive nephropathy or renovascular 
complications, it is more commonly the consequence of ischaemic and toxic insults. It is 
associated with high morbidity and mortality, particularly in critically ill and elderly patients, 
with mortality numbers reaching up to 60%
1-3
. Because no specific pharmacologic therapy is 
effective in AKI patients, their care is limited to supportive management such as renal 
replacement therapy. The high mortality rate and its associated cost make AKI a serious 
public health concern and an important economic burden for healthcare systems world-wide.
4-
6
. To be more specific, it has been reported to cost 434-620 million pounds in the United 





Renal ischaemia-reperfusion injury (IRI) is a common cause of AKI. It occurs when 
the blood supply to the kidney is reduced or completely abolished and then restored. Both the 
deprivation and restoration of oxygen and nutrients contribute to tissue damage. While tissue 
damage is initiated by the former, restoration of blood flow causes exacerbation of tissue 
injury culminating in a profound inflammatory response (reperfusion injury). IRI takes place 
in the clinical setting during kidney transplantation, kidney tumour resections, and cardiac or 





 1.1.2. Pathophysiology of kidney ischaemia-reperfusion injury  
 
Kidney ischaemia-reperfusion injury triggers a cascade of complex mechanisms that 
lead to epithelial and endothelial cell injury, as well as hemodynamic instability. As a result, 
the innate and adaptive immune responses are activated, leading to sterile inflammation and 
oxidative stress that further aggravate injury (Fig.1). The lack of oxygen will lead to ATP 
depletion and will cause damage in all segments of the nephron. Due to their higher metabolic 
rate proximal tubular epithelial cells in the S3 segment will suffer the most, losing their apical 




Likewise, endothelial cells are profoundly damaged when subjected to ischaemia. 
Increased levels of endothelin-1, angiotensin II as well as reduced production of NO cause 
vasoconstriction in the small arterioles of the post-ischaemic kidney. This, together with 
activation of the coagulation system and oedema formation, causes vascular occlusion, 
thereby further reducing blood flow to the outer medulla
12
. Endothelial injury also leads to 
impairment of the vascular barrier, supporting oedema formation and leucocyte egress. 
Subsequently, these leucocytes become activated, starting to produce inflammatory cytokines 




 Both innate and adaptive immune responses play an important role in IRI. The innate 
response acts as early as 30 min after IRI, in a non-antigen-specific fashion, involving 
neutrophils, monocytes, macrophages, DC, NK cells and NKT cells (natural killer T cells). 
The role of adaptive immune response in kidney IRI is not yet fully understood, but it is
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believed that T-cell activation occur both through antigen-specific and antigen-
independent mechanisms, and it takes place hours or days after the initial injury 
14,15
. The first 
wave of immune cells are neutrophils, which attach to the endothelium and produce proteases, 
ROS and cytokines, leading to increased vascular permeability and cell injury. Facilitated by 
the action of CCR2 and CX3CR1 signalling pathways, the second wave of cells that infiltrate 
the kidney consists of monocytes. Their main action is phagocytosis and digestion of cellular 
debris. They also can differentiate into M1 or M2 tissue macrophages, special subsets of 





In the course of IRI the complement system is activated, mostly but not exclusively, 
through the alternative pathway. This further propagates the inflammatory cascade. In 
particular, formation of C5a supports neutrophil recruitment, macrophage activation and 
chemokine production by the tubular epithelium
18,19
. In response to epithelial cell damage, 
these cells express toll-like receptors (TLRs), mostly TLR2 and TLR4, which associated 
molecular patterns (DAMPs) in the extracellular milieu of damaged cells and upon receptor 
engagement execute a pro-inflammatory response reflected by cytokine production and more 
recruitment of inflammatory cells. TLR expression/activation is increased under hypoxic 




The role of T-cells in kidney IRI has not been fully elucidated yet. Rodent models of 
IRI using T-cell deficient animals have suggest a pivotal role for CD4 T cells 
22,23
. Likewise it 
seems that NKT cells, a subset of T-cell receptor expressing NK cells, infiltrate the post-
ischaemic kidney as soon as 3 hours after IRI producing large amounts IFNγ 
24
. The later 
mediator, also upregulates MHC class I and II molecules on non-hematopoietic cells, like 




Generation of ROS in IRI comes from four pathways: the mitochondrial respiratory 
chain; NADPH oxidases; reaction of arachidonic acid catalysed by cyclooxygenase 2; and 
xanthine and hypoxanthine via xanthine oxidase. The latter is activated under ischaemic 
conditions, enabling the oxidation of hypoxanthine to xanthine upon reperfusion 
concomitantly with formation of free oxygen radicals
26
. ROS may cause direct damage to 
cells through lipid peroxidation of the cell membrane, or indirectly via the formation of the 
highly toxic peroxynitrite. The huge amount of ROS overwhelms the capacity of oxidant-
scavenging systems, leading to mitochondrial dysfunction, compromised ATP production, 





1.1.3. Progression to chronic kidney disease  
 
For several years it was believed that AKI was a reversible process that would 
eventually lead to full recovery in absence of co-morbidities. However, evidence from several 
epidemiological studies suggests that AKI is a risk factor for the progression to chronic 
kidney disease (CKD)
30-35
. Kidney fibrosis is a key feature of progressive chronic kidney 
disease and it is characterised by an excessive deposition of a collagenous extracellular matrix 
(ECM). This is mainly attributed to the secretion of profibrotic cytokines by inflammatory 
cells, resulting in fibroblast and myofibroblast activation
36
.  




Figure 1: Main pathophysiological events occurring during kidney ischaemia-
reperfusion injury.  
A. Proximal tubular epithelial cells are damaged due to ATP depletion caused by oxygen 
deprivation. As a result, they lose their characteristic brush border and detach from the basement 
membrane, causing tubular dilation. In response these cells express TLR2 and TLR4, which bind to 
the DAMPs released to the extracellular compartment and enhance the inflammatory response by 
recruiting inflammatory cells and producing pro-inflammatory cytokines. Additionally, the 
complement system is activated, further promoting inflammation. B. Endothelial cell injury leads to 
vasoconstriction of small arterioles in post-ischaemic kidney due to increased levels of vasoconstrictor 
agents (endothelin1 and angiotensin-II) and decreased production of vasodilators (NO). Furthermore, 
vascular permeability is disturbed causing leucocyte activation and migration into the vessels, 
facilitated by the upregulation of ICAM and VCAM. The first wave of cells are neutrophils, whose 
main mechanism of injury is ROS production. Secondly, macrophages infiltrate the tissue and 
differentiate into M1 (pro-inflammatory cytokine producing) or M2 (inflammation resolution) 
subtypes. Finally, T cells are activated in antigen independent (by cytokines produced by macrophages 
or DCs, or through complement activation) or antigen dependent fashion (through the action of 
antigen-presenting cells). 
DAMPs: Danger-associated molecular patterns; TLR: Toll-like receptor; NO: Nitric oxide; 
ICAM: Intracellular adhesion molecule; VCAM: Vascular cell adhesion protein; ROS: Reactive 
oxygen species; MIP-1: Macrophage inflammatory protein 1; APC: Antigen-presenting cell; TCR: T-
cell receptor; MHC-II: Major histocompatibility complex II.  
 
 
The mechanisms involved in the progression from AKI to CKD are not yet fully 
understood; however, it is believed that they are associated with incomplete or abnormal 
repair
37,38
.During the normal repair proximal tubular epithelial cells first undergo 
dedifferentiation, then migrate along the basement membrane, proliferate and finally 
differentiate to replace the injured cells. If however IRI causes severe damage, cells become 
senescent resulting in maladaptive repair
38,39
.This repair leads to incomplete restoration of  
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kidney tissue integrity, persistent inflammation, activation of pericytes, accumulation 
of myofibroblasts and ECM deposition
40,41
. If cell damage includes DNA strand breaks this 
will hamper cell proliferation due to a G1 cell cycle arrest required for the DNA damage 
response. All these events collectively may lead to epigenetic changes in fibroblasts that 
persist long after the initial injury
42,43
. It is believed that these alterations create a fundament 




1.1.4. Animal models of warm ischaemia  
 
Animal models of warm ischaemia have been crucial to understand the mechanisms 
involved in kidney IRI. They are by far the most commonly used AKI models reported in 
literature
44
.Transient renal ischaemia is produced by clamping the renal pedicle for a variable 
amount of time (usually between 30 and 90 minutes)
45
. Bilateral ischaemia is one of the oldest 
models studied. It has the advantage of resembling the clinical scenario, as both kidneys are 
usually equally affected during ischaemia or hypoperfusion and it allows following the 
function of two ischaemic kidneys. However, due to its severity, longer ischaemia times are 
not permitted, as higher mortalities will follow
46
. Unilateral kidney ischaemia models are 
either performed with or without contralateral nephrectomy. Unilateral kidney ischaemia with 
contralateral nephrectomy is the most frequently used model to induce ischaemic AKI and 
allows renal function monitoring of the damaged kidney. Yet also this model does not permit 
longer ischaemia periods for similar reasons as mentioned above
47,48
.In recent times, 
unilateral ischaemia without contralateral nephrectomy has gained relevance. This model 
allows longer ischaemia periods, as loss of renal function will be compensated by the non-
ischaemic kidney. Hence, renal function monitoring of the ischaemic kidney cannot be 
performed in the acute phase, but can be assessed at later time points when the non-ischaemic 
contralateral kidney is removed 
46,49




1.2.  Kidney transplantation: An overview  
 
The first successful kidney transplant in humans was performed in 1954 by Joseph 
Murray, using identical twins as donor-recipient combination. Because of the lack of powerful 
immune suppressive drugs, renal transplantation was not an effective treatment for patients 
with end-stage renal disease. Although the work of Sir Roy Calne in the 1960s marked the 
beginning of the immunosuppressive therapy in renal transplantation, graft survival was still 
poor because the use of steroids alone was not adequately preventing graft rejection. It was in 
the mid-1980s, with the implementation of calcineurin inhibitors when transplantation 
medicine grew exponentially, leading to graft survival of approximately 80% after one year at 
that time
50,51
.    
 
Since then, kidney transplantation has become the treatment of choice in patients with 
end-stage renal disease (ESRD), providing improved quality of life and increasing life 
expectancy and quality
52
. Nevertheless, despite huge advances in immunosuppressive 
therapies, organ matching, preservation and donor management, chronic graft loss has not 
significantly changed over time and remains a scientific and clinical challenge. Consequently, 
50% of renal recipients return to dialysis within 10 years
53
. Furthermore, the demand for 
organ transplantation has increased worldwide, while the supply of suitable organs to cover 
this demand has not been able to be met. Specifically, in Europe, patients in need of a kidney 
transplant are around 120-140 million, whereas organ availability is 14-21 million. Therefore, 
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patients spend approximately 5-10 years on the waiting list. In the meantime they have to 
rely on dialysis, which is associated with a high mortality, meaning that patients might die 





1.2.1.  Alloantigen-dependent factors affecting transplantation outcome 
 
Transplantation outcome is greatly determined by humoral and cellular immune 
responses against the foreign donor MHC molecules. This explains the benefit of HLA 
matching on graft survival. Humoral and cellular immune responses give rise to distinct types 
of rejection. Also the target cell that is being attacked by these responses as well as the time 
frame of occurrence is important for the classification/diagnosis of the different types of 
rejection. In general, rejection can be antibody-mediated (AMR) or T-cell-mediated (TMR) 




 Antibody-mediated rejection is primarily directed against the vasculature. Based on 
the time frame of occurrence AMR is defined as hyperacute, acute or chronic. Hereunder 
these types of rejection will be discussed: 
 
 Hyperacute rejection takes place almost immediately after reperfusion and it is the 
result of the antibody deposition on the endothelium leading to complement activation 
through the classic pathway. These antibodies may be directed against HLA antigens, blood 
group antigens or against unknown endothelial antigens. Apart from complement activation, 
coagulation pathways are activated leading to thrombus formation, occlusion of the 
microvasculature and finally to irreversible graft loss. With the improvement of pre-




 Acute antibody-mediated rejection begins within days or months after kidney 
transplantation and it is clinically manifested by a rapid increase in serum creatinine and non-
responsiveness to treatment with steroids or drugs targeting T-cell activity
59
. Recipient 
antibodies against donor MHC antigens that are displayed on the endothelial cells and 
glomerular capillaries bind. Thereafter, endothelial cells release deleterious molecules like 
Von Willebrand factor and P-selectin, which cause platelet aggregation, thrombus formation 
and production of IL-1α, IL-8, CCL2. This leads to leukocyte migration to the glomeruli and 





 Chronic antibody-mediated rejection is the major cause kidney graft failure. It occurs 
months to years after kidney transplantation as a response to pre-existing donor-specific 
antibodies or antibodies generated after transplantation. These antibodies are deposited on the 
endothelium of glomerular and peritubular capillaries, leading to endothelial injury 
manifested in the form of endothelial cell hypertrophy, subendothelial deposition of fibrilar 





 T-cell-mediated rejection is mostly mediated by alloreactive T-cells that recognize 
the foreign HLA on tubular epithelial or on endothelial cells of the vasculature. It can occur in 
an acute or chronic manner: 
 
 Acute T-cell mediated rejection is diagnostically defined as infiltration of mononuclear 
cells in the tubules (tubulitis). T-cells may also infiltrate the vasculature (vasculitis/arteritis, 
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 i.e. T-cell mediated vascular rejection). The incidence of acute T-cell-mediated 
rejection with the current therapies targeting T cell activity is relatively low (5-10% in the 
first year in unsensitised patients). The interstitial infiltrate is composed mostly of CD4+ and 
CD8+ T cells, whereas epithelial tubular cells upregulate ICAM-1, CD80 and CD86 and 
therefore, recruit macrophages as well as T cells. Endarteritis is detected in 25-40% of renal 
biopsies, and it is characterized by subendothelial accumulation of mononuclear cells and 




Chronic T-cell-mediated rejection is the result of failure to maintain sufficient 
immunosuppression in order to avoid a sustained infiltration of T-cells and macrophages over 
time. It is characterized by transplant vasculopathy, which is a progressive narrowing of the 
lumen of the vessels that eventually compromises the blood flow to the graft and leads to its 
failure
62
. One of the most accepted theories to explain this phenomenon is an “inside out” 
hypothesis. According to it, the chronic allogeneic response targets first the endothelium 
(tunica intima). The injured endothelial cells and macrophages (that migrated in response of 
pro-inflammatory cytokines and adhesion molecules) produce growth factors (VEGF) and 
IFN-γ, which stimulate phenotypic changes in the smooth muscle cells of the tunica media. 






1.2.2. Alloantigen-independent factors affecting transplantation outcome  
 
The benefit of HLA matching on graft survival has underscored the relevance of the 
HLA system for transplantation outcome. Yet, recipients that receive a mismatched renal 
allograft from a living donor in general have a better transplantation outcome compared  that 
of recipients with a well matched renal allograft from a deceased donor
64
. This argues against 
the importance of HLA and suggests that additional factors likely are playing pivotal roles in 
transplantation outcome. These alloantigen-independent factors include amongst others donor 




 Renal allografts can be obtained from deceased brain dead donors (BDD), deceased 
circulatory dead donors (CDD) or living donors (LD). Due to organ shortage and increased 
time on the waiting list, the use of renal allografts from LD has gained prominence. In the last 
years, 27000 related and unrelated living-donor transplantations were performed in the 
developed countries. Recipients of living-donor kidneys have lower risk of rejection and 
better allograft survival (87,2% survival after 5 years). This is partly due to the much shorter 
cold ischaemia time (organ explantation and implantation take place in the same 
transplantation centre), but also to the fact that the donor did not suffer from brain or 
circulatory death
66,67
. Because cold ischaemia favours intracellular calcium accumulation, 
cellular acidosis and mitochondrial dysfunction the short cold ischaemia time in LD clearly 




 Brain death (BD) initiates a cascade of hemodynamic instability (‘catecholamine 
storm’), hormonal, metabolic, and inflammatory events (release of pro-inflammatory 
cytokines, complement activation) that affect the quality of the organs and increases their 
immunogenicity. Compared to LD grafts from BDD have significantly more delayed graft 
function and decreased allograft survival (71,1% survival after 5 years) 
69-71
. On the other 
hand, circulatory death (CD) can happen under uncontrolled circumstances (death out of 
hospital, unsuccessful resuscitation) or controlled conditions (patients in the ICU, patients 
who arrest in the operating theatre or who suffer cardiac arrest while brain dead). Because of 
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 the lack of circulation, CD is associated with prolonged warm ischaemia times. These 
organs suffer significantly more from delayed graft function and have increased rejection 




 Transplanted kidneys are subjected to ischaemia and ischaemia-reperfusion injury at 
different moments. The first warm ischaemia occurs at the time of cross-clamping before 
perfusions with cold preservation solution. The organ remains ischaemic (cold ischaemia) 
while in transit to the transplantation centre after having been flushed with a preserving 
solution. The second warm ischaemia occurs during anastomosis, where the organ warms up 
to reach the body temperature of the recipient
74
. If the kidney is not adequately perfused after 
anastomoses this may further increase regional ischaemia, also referred to as the no-reflow 
phenomenon
75
. Reperfusion injury takes place, when the organ is ultimately perfused with the 
blood of the recipient at 37°C. Therefore, ischaemia-reperfusion injury is an unavoidable 
event in solid organ transplantation, and is a major cause of early graft dysfunction and 
rejection
76
. Its role in triggering the innate and adaptive immune responses has already been 
discussed in section 1.1.2.  
 
 
 1.2.3. Fischer to Lewis model of chronic renal allograft rejection  
 
The Fischer to Lewis model was the first chronic kidney allograft rejection model in 
rats reported in literature in 1969
74
. Ever since, it has been extensively used to elucidate 
mechanisms of rejection as well as to test the efficiency of a number of treatment 
modalities
77,78
 .In this model, the Fischer rat (F344/ ) acts as a donor and the Lewis rat 
(Lew/RT1¹) as the recipient. Initially it was believed that these strains differed at weak 
histocompatibility loci, but now it is known that they differ at two expressed MHC class I-like 
genes (RT1.C) and various non-MHC genes (RT6). IgM and IgG alloantibody production has 
been described in this model, although their circulating levels may decline after 2-4 weeks, 
and are only present sporadically thereafter
79
. It is reported that progression to chronic 
rejection starts at 4 weeks, when mild mononuclear cell infiltration, minor proliferation of 
mesangial cells and occasional thickening of the glomerular basement membrane is observed. 
At 8-12 weeks, there is significantly more mononuclear cell infiltration of vessels and 
glomerular changes, leading to proteinuria. At 28 weeks, extensive interstitial fibrosis and 
vascular intimal thickening with mononuclear cell infiltration is observed, and complete 






1.3. Rationale of the use of mesenchymal stromal cells in kidney injuries 
 
 Multipotent mesenchymal stromal cells (MSC) were first described by Friedenstein 
et.al in 1970, when they isolated fibroblast-like colonies from the bone marrow of Guinea 
pigs
81
. They are mesoderm-derived cells with self-renewal capacity that can be isolated from 
different adult or foetal sources: bone marrow, adipose tissue, periosteum, synovium, dental 
pulp, umbilical cord tissue and blood, placenta and amniotic fluid, among others.
82
 To date, 
there is no specific marker to identify MSC, and thus, their in vivo functions are not fully 
known. However, they are believed to sustain homeostasis in hematopoietic niches as well as 
to support the in vivo homeostasis of other progenitor cells through the secretion of trophic 
factors like stem cell factor, platelet-derived growth factor, macrophage-colony stimulating 
factor (M-CSF), erythropoietin (EPO) and angiopoietin-1(Ang-1)
83
. 
Introduction and aims - 12- 
 
 
 Due to the lack of specific markers, the International Society for Cellular Therapy 
determined the minimal criteria to define MSC:  
 
1. Plastic adherence under standard culture conditions and a fibroblastoid phenotype 
2. More than 95% of the cell population must be positive for antigens absent in 
haematopoietic cells: CD105, CD73 and CD90. Besides, up to 2% can express CD45 
(leucocytes), CD34 (haematopoietic progenitor), CD14 or CD11b (monocytes and 
macrophages), CD79α or CD19 (B-cells), and HLA-DR (antigen presenting cells and 
lymphocytes) surface molecules 
3. Potential to differentiate into adipocytes, chondrocytes and osteoblasts. 84 
 
 The use of MSC as a potential therapeutic modality in different fields of regenerative 
medicine has been a subject of study for decades. In those studies it has been shown that MSC 
are able to modulate the immune response, show anti-inflammatory, anti-apoptotic, anti-
oxidative, and anti-fibrotic capacity, as well as angiogenic properties
85
 (Fig.2).   
 
 
1.3.1. Immunomodulation  
 
From different in vitro and in vitro studies it is known that MSC are able to induce an 
effect in all types of cells of the immune system, although all the exact mechanisms involved 
are not yet fully known. One of the main interactions studied are those between MSC and 
macrophages, and the general consensus is that MSC are able to induce polarization of 
macrophages from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype. This switch 
has been shown to be promoted by the secretion of  prostaglandin E2 (PGE2)
86
 by MSC as 
well as by the secretion of IL-1 receptor antagonist (IL1-RA)
87
.Moreover, polarization of M2 
macrophages can also take place through cytokine-independent mechanisms, as it has been 
reported that when MSC are phagocytosed by monocytes/macrophages it causes a 
polarization toward CD14++, CD16+ and CD206+ regulatory subtypes, with anti-
inflammatory properties, like production of IL-10 and increased expression of PD-L1
88
. MSC 
have been proven to interfere in DC maturation by downregulation of maturation markers and 
costimulatory molecules (CD80/CD86)
89
. In the presence of MSC, DC are less efficiently 




Independent of their effect on DC, MSC can directly suppress T-cell activation. One 
of the postulated mechanisms accountable for this is IDO (indoleamine 2,3-dioxygenase) 
secretion, which catalyses the conversion of tryptophan, essential to T cell activation. In 
CD4+ Th1 cells, MSC induce the downregulation of the IFN-γ receptor, thus reducing their 
IFN-γ mediated susceptibility
91
. Similarly, in CD4+ Th2 cells, MSC have been shown to 
inhibit IL-4 and IL-5 production. In addition to that, their effect inhibiting CD8+ T cells seem 





MSC also have the capacity to induce regulatory T cells (Tregs). This is partly 
mediated by TGF-β1 production but seem to require the presence of monocytes. It is believed 
that MSC favour M2 macrophage differentiation which leads to CCL18 production. The latter 
chemokine plays a pivotal role in the induction of Tregs
92,94
. Tregs are part of the peripheral 
tolerance mechanisms and have important roles in shaping the immune response. 




MSC interactions with B cells are much less researched. Some studies have 
highlighted the ability of MSC to induce regulatory B-cells (Bregs) that like Tregs modulate 
immune responses
95,96
. Finally, NK cells are also powerfully inhibited by MSC, impairing 
their cytotoxic cytokine production potential. These effects are mediated by MSC production 









Figure 2: Mechanisms of action of MSC supporting their therapeutic potential. A. MSC are 
mesoderm-derived, fibroblast-like cells than can be isolated from adult or foetal sources. B. One of the 
mechanisms supporting MSC therapeutic capacities is their ability to differentiate into different cell 
types of mesoderm origin, in vitro and in vivo. C. Immunomodulation is one of the most widely 
studied properties attributed to MSC, as they can exert effects on all cell types of the immune system 
mainly by inhibiting their pro-inflammatory potential, and helping inflammation resolution. D. 
Secretion of paracrine factors is recognised as the main mechanism of action of MSC. These factors 
comprise the MSC secretome, constituted of different kind of proteins (growth factors, angiogenic 
factors, chemokines, cytokines) and extracellular vesicles, all of which have been shown to present 
anti-inflammatory, angiogenic and regenerative potential. 
 
HGF: Hepatic growth factor; IGF: Insulin-like growth factor; TGF-β: Transforming growth factor 
beta; bFGF: Basic fibroblast growth factor; VEGF: Vascular endothelial growth factor; M-CSF: 
Macrophage colony stimulating factor. 
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1.3.2. Role in fibrosis, angiogenesis and apoptosis  
 
MSC are also reported to reduce tissue fibrosis, not only by decreasing overall 
inflammation, but also by favouring ECM degradation through suppression of tissue inhibitor 
of metalloproteinase (TIMP) activity
99
. Furthermore, MSC treatment has been shown to 
reduce the expression of TGF-β1 and α-SMA in several pre-clinical models 
100
. Some of these 
actions have been mediated by TNF-stimulated gene 6 (TSG-6), released by MSC when in 
co-culture with activated macrophages
101
. It seems that MSC also mediate anti-oxidative 




The role of MSC in angiogenesis is known to be mediated by enhancement of different 
growth factors like VEGF, bFGF and HGF, but also by the action of MSC-derived 
extracellular vesicles (MSC-EV)
104,105
.The secretion of growth factors seems to be also 
involved in their anti-apoptotic properties, together with the upregulation of anti-apoptotic 




 All of these properties together, make MSC eligible candidates for cell based 
treatment of AKI or to prevent the progression to CKD. Because currently used 
immunosuppressive therapies in renal transplantation mostly include calcineurin inhibitors 
that by themselves have adverse effects for the kidney
85,106
, the use of MSC in kidney 
transplantation may not only diminish allogeneic immune responses but also may help in 
establishing calcineurin inhibitor free or nearly free immunosuppressive regimens. 
 
 
1.3.3. MSC secretome: conditioned media  
 
In vivo studies using MSC have shown that intravenously injected MSC are 
preferentially trapped into the lung circulatory system and only a minor fraction of cells reach 
other organs, including secondary lymph nodes
107
. In addition to that, it has also been 
reported that MSC are no longer detectable 24-72 hours post-injection, even though a 
beneficial effect is observed 
108
. In keeping with this, the question that needs to be addressed 
is how MSC exert their therapeutic activity if they don’t reach the target organ? Some authors 
suggest that MSC can differentiate into glomerular mesangial cells and tubular epithelial 
cells,
109,110
 whereas more recent studies suggest that the beneficial effects occur through 
secretion of autocrine and paracrine factors 
111
. The latter explanation has been reported in at 
least 80% of preclinical studies, being the most accepted hypothesis on how MSC mediated 
therapeutic effects
112
. The paracrine factors are mostly referred as stem cell secretome, 
containing different types of proteins, mRNAs, miRNAs, antioxidants wrapped in 
extracellular vesicles. The cell culture that comprises this secretome is referred to as 
conditioned media (CM)
113
.   
 
Several preclinical studies have shown the efficacy and safety of MSC-derived CM 
(MSC-CM), even when used in xenogeneic combinations of stem cell donor and recipient. In 
a porcine model of myocardial infarction, human MSC-CM was able to reduce myocardial 
nuclear oxidative stress and decrease de phospho-Smad2 and active caspase 3, resulting in a 
60% reduction of infarct size and enhancement of systolic and diastolic heart performance 
114
. 
Also, in an antigen-induced arthritis model in mice, it was found that when treated with CM-
MSC, CD4+T cells showed increased FOXP3 and IL-4 expression leading to decreased knee 
swelling and histopathological signs of cartilage loss
115
. Furthermore, ASC-CM has also been 








 Additionally, the use of extracellular vesicles (EVs) derived from MSC (MSC-EVs) as 
a therapeutic strategy has gained relevance in the last few years. Depending on their origin 
and size, EVs can be classified as microvesicles, exosomes and apoptotic bodies. 
Microvesicles (100-1000 nm) originate from direct budding of the plasma membrane. They 
contain surface receptors and biologically active molecules like proteins and lipids as well as 
mRNA and miRNA. Exosomes (40-100nm) are secreted by multivesicular bodies and play an 
important role in immunomodulation and cell-to-cell communication. Apoptotic bodies (1-
5µm) on the other hand, are released from the plasma membrane when cells undergo 
apoptosis and contain intracellular fragments, organelles and fragmented DNA; nevertheless, 




 EVs have been used in some preclinical studies with promising results. For instance, 
when used in a fully MHC mismatched transplantation model in rats, MSC-MV ameliorated 
outcome by reducing the number of NK cells and the expression of TNF-α
118
. Likewise, 
MSC-MV enhanced tubular cell proliferation, reduced apoptosis and leukocyte infiltration in 
an ischaemia-induced AKI model in rats. Interestingly, the protective effect was lost when 
RNase treatment was implemented; suggesting that miRNA transfer from MV to the injured 
cells is one of the mechanisms involved
119
. Thus, since MSC-CM and MSC-EVs use in 
preclinical models has been reported to show promising preliminary results, their use as a 
prospective replacement to MSC therapy seems feasible. Compared to the use of MSC, cell-
free therapy presents several advantages, like cheaper production and lower immunogenicity 
and carcinogenic potential
113
.   
 




1.4. Aims of the thesis  
 
Epidemiological studies have revealed that AKI is a risk factor for progression to 
CKD.
32,33
 Murine models of AKI are mostly based on renal ischaemia, and are less 
susceptible to chronic renal function deterioration in long-term observation studies. The 
different models of ischaemia-induced AKI are controversially discussed, with no consensus 
as to whether chronic renal function deterioration is influenced by removal of the contralateral 
kidney at the time of ischaemia
46
. The main option for the treatment of patients with AKI 
remains the provision of supportive care and renal replacement therapy. Hence the lack of 
treatment modalities underscores the unmet need for better translational models for testing 




Stem cells, as well as stem cell secretome-based therapies have emerged as potential 
candidates for improving the clinical outcome of patients suffering from AKI. Nevertheless, 
their exact mechanisms of actions are not fully understood, emphasizing the need for animal 
models that more closely resemble the clinical sequel that underlies the progression to CKD. 
Since human MSC and ABCB5+ stromal cells are currently tested in clinical trials, these cells 




This study underlies the hypothesis that human MSC and MSC-CM can mitigate long-
term renal function deterioration following AKI in rodent models. These models need to be 
sufficiently strong, displaying significant chronic histopathological changes in renal tissue.  
 
To this end, the following questions are addressed:  
 
1. Is a single severe episode of unilateral kidney ischaemia without contralateral 
nephrectomy able to induce sufficient long-term injury? What are the main 
histopathological features of this injury? Does it lead to long-term renal function 
impairment? 
 
2. What is the difference in terms of long-term functional and morphological outcomes 
between removal and non-removal of the contralateral kidney at the time of ischaemic 
injury?  
 
3. Can human adipose-derived MSC improve major structural and functional parameters 
in this model?  
 
4. Can chronification of injury be increased by implementing cold ischaemia and minor 
MHC disparity? Is this reflected by GFR deterioration? 
 
5. What is the influence of human ABCB5+ cells and its derived conditioned media on 
the major functional and histopathological features of this model?  
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2. Material and Methods 
 
2.1. Experimental designs  
 
 2.1.1. Assessment of long-term renal outcomes in a model of ischaemia-induced 
acute kidney injury without contralateral nephrectomy  
 
Acute kidney injury was induced by clamping the left renal pedicle of non-
uninephrectomised Lewis rats for 60 minutes.  
 
Prior to the beginning of the experiments, animals were randomly allocated in two 
different groups, as follows: 
 
Group 1: AKI Nx170 (n=6) 
AKI-induced animals, right nephrectomy at day 170 after injury 
Group 2: Control Nx170 (n=6) 
Non AKI-induced animals, right nephrectomy at day 170  
 
 
The day of AKI induction surgery was considered day 0. One day before injury 
animals were placed into metabolic cages, to monitor their weight and to collect and quantify 
the urine produced in 24 hours. Thereafter, blood sampling was performed by retrobulbar 
plexus puncture, and the transcutaneous measurement of kidney function was also assessed. 
These procedures were repeated at day 1, 3, 150, 166 and 177 after AKI induction.  
 
Animals in both groups underwent right nephrectomy at day 170. In the case of the 
control group, nephrectomy was performed taking as a reference the day that age-matched 





 Fig.3: Experimental plan followed for the assessment of long-term renal outcomes in a model 
of unilateral kidney ischaemia without contralateral nephrectomy at the time of injury. 
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2.1.2. Assessment of long-term renal outcomes using two different models of 
ischaemia-induced acute kidney injury 
 
Acute kidney injury was induced in Lewis rats that had been either uninephrectomised 
or not at the time of injury. Prior to the beginning of the experiments, animals were randomly 
allocated in different groups, as follows: 
 
Group 1: AKI Nx170 (n=6) 
AKI-induced animals, right nephrectomy at day 170 after injury 
Group 2: Control Nx170 (n=6) 
Non AKI-induced animals, right nephrectomy at day 170  
Group 3: AKI Nx0 (n=9) 
AKI-induced animals, right nephrectomy at the time of injury (day 0)  
 
The same experimental plan as described in section 2.1.1 was followed, with the addition of 





 Fig.4: Experimental plan followed for the assessment of long-term renal outcomes in a model 




2.1.3. Assessment of the therapeutic efficacy of human adipose-derived 
mesenchymal stromal cells (hASC) in an ischaemia-induced AKI model  
 
For this set of experiments, the same plan as described in section 2.1.1 was followed, 
with the addition of the treatment with 1x of hASC or 500 µL of vehicle (NaCl, 0,9%) 14 
days after AKI induction (Fig.5).  
 
Animals were randomly assigned into different groups, as follows:  
 
Group 1: AKI Nx170 (n=6) 
AKI-induced animals, right nephrectomy at day 170 after injury 
Group 2: Control Nx170 (n=6) 
Non AKI-induced animals, right nephrectomy at day 170  
Group 3: AKI Nx170+hASC (n=10) 
AKI-induced animals, hASC-treated 14 days after AKI induction (IV) 
 






 Fig.5: Experimental design followed to assess the efficacy of hASC in an ischaemia-induced 
AKI model without contralateral nephrectomy at the time of injury.  
 
 
2.1.4. Assessment of therapeutic efficacy of human ABCB5+ cells and its derived 
CM in a chronic kidney allograft rejection model  
 
In these experiments, the left kidney of Fischer 344 rats was explanted, in order to be 
implanted orthotopically 8 hours later, after cold storage, in an age-matched Lewis rat. 
Histidine-tryptophan-ketoglutarate-solution (HTK solution) was used for organ perfusion and 
as preservation solution during cold storage. 
 One day before transplantation, recipients were treated with either hABCB5+ 
cells or 500 µL of hABCB5-derived CM intravenously (tail vein). To assess the function of 
the transplanted graft, the right kidney of the recipients was removed 10 days after surgery. A 
second injection of either hABCB5+ cells or 500 µL of hABCB5-derived CM was 
performed 17 days after kidney transplantation.  
 
Follow up of general condition, weight, and kidney function was assessed every two 
weeks by collecting plasma samples and urine, placing the animals in metabolic cages for 24 
hours.  
 
An end-point transcutaneous kidney function measurement was performed, one day 
before sacrifice, which took place 98 days after kidney transplantation (Fig.6). 
 
 
Animals were randomly allocated in different groups, as follows: 
 
Group 1: KTx control (n=7) 
Transplanted animals, untreated 
Group 2: KTx+hABCB5 (n=7) 
Transplanted animals treated with hABCB5+ cells (IV) 
Group 3: KTx+CM- (n=5) 












 Fig. 6: Experimental design followed to study the efficacy of hABCB5+ cells and CM in a 




2.2. Surgical methods  
 
Every procedure was performed according to the Guide for Care and Use of 
Laboratory Animals published by the National Academy of Sciences and were approved by 
the local authorities (RP Karlsruhe AZ 35-9185.81/G-240/16 and AZ35-9185.81/G-153/14). 
 
All the operations that will be described utilised micro surgical techniques. For that 
reason, a binocular cold-light microscope with 6-40x objectives was used (Leica MZ6, Leica 
Microsystems Wetzlar, Germany) as well as an anaesthetic vaporizer (SurgiVet®, Smith 
Medicals PM, Massachusetts, USA) for anaesthetic maintenance. The core temperature of the 
animals was kept at 37°C by placing them on a heating table (MEDAX GmbH Neumünster, 
Germany) during the whole duration of the procedures.  
 
 
2.2.1. Warm ischaemia model (acute kidney injury induction) 
 
Inbred male Lewis (LEW/Crl) rats weighing 200-250g were obtained from Charles 
River (Sulzfeld, Germany). Animals were kept in standard conditions and fed standard rodent 
food and tap water ad libitum.  
 
To induce anaesthesia, animals were  placed into a sliding-top induction chamber 
(Kent Scientific, Torrington, CT, USA) connected to the anaesthetic vaporizer, delivering 
isoflurane (CP-pharma, Burgdof, Germany) (3-4% 1L/min 0₂). Afterwards, a mixture of 
Ketamin (100 mg/mL; Ketamin® Wirtschaftsgenossenschaft deutscher Tierärtze eG, 
Garbsen, Germany) and xylazin (6 mg/mL; Serumwerk Bernburg, Bernburg, Gerrmany) was 
administered IP .To maintain anaesthesia, isoflurane was delivered to the animals (1,5-2% 
1L/min 0₂) through a mask connected to the vaporizer.  




Next, and after checking the onset of anaesthesia by toe pinch and corneal reflex, the 
hair from the abdomen was shaved and the skin disinfected (Softasept ®, B.Braun, 
Melsungen, Germany). To protect the cornea from drying, an eye ointment was used 
(Bepanthen®, Bayer GmbH, Leverkusen, Germany). Afterwards, 100 IU/animal of heparin 
(Heparin-Natrium-25000®, Rathiopharm ,Ulm, Germany) were injected into the caudal vein 
(tail vein) to avoid clot formation.  
 
Then, a midline incision was performed, first on the skin, separating it from the 
subcutaneous tissue, and then through the linea alba, from the xiphoid process to the pelvis. 
To better visualize the left kidney, the caecum and the small intestine were placed to the right 
























Fig.7: Overview of the abdomen of a rat after laparotomy. 1. Left kidney, 2. V.renalis, 3. Left 




Once the left kidney was clearly visible and the renal artery and vein were accessible, 
two holes were open with the help of curved forceps (S&T Vessel Dilating Forceps angled 
45°, Fine Science Tools, Heidelberg, Germany), one cranial to the renal artery and the other 
caudal to the renal vein. In these holes the atraumatic vascular clamps were placed, first the 
one occluding the renal artery (Micro Serrefines 4x 0,75 mm, Fine Science Tools, Heidelberg, 
Germany) and then the one obstructing the blood flow to the renal vein (Micro Serrefines 
8x2mm,Fine Science Tools, Heidelberg, Germany). Success of the procedure was confirmed 
when the kidney turned from pale pink to dark purple due to the complete lack of blood 
circulation (Fig.8).  




Ischaemia time was set to 60 minutes. In this period, the abdomen was covered with a 
damp swab to avoid dryness and the temperature of the animals was checked every 10 
minutes. When the 60 minutes had passed, the clamps were released, first the venous clamp 
and then the arterial clamp. The kidney turned back to its physiological colour within a few 
seconds. To compensate for possible fluid loss, 2mL of NaCl 0,9%  (Fresenius Kabi, Bad 
Homburg, Germany) were infused into the abdominal cavity. The abdominal wall and skin 
were closed using a continuous suture (3/0 Surgicryl PGA, SMI, Steinerberg, Belgium) and 

























 Fig.8: Overview of the operation field during warm ischaemia. 1. Ischaemic left kidney, 2. 





Animals were then placed into a separate cage under a red light lamp to allow them to 
recover from the anaesthesia. To provide analgesia, 0,05mg/kg of buprenorphine 
hydrochloride (Buprenovet® Bayer GmbH, Leverkusen, Germany) was administered SC. 
Once animals were awake, they were placed into a separate cage with free access to food and 
water until the wound was completely closed.  
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2.2.2. Kidney transplantation  
 
Male Fischer rats (F344/DuCrl) were used as donors and male Lewis rats (LEW/Crl) 
as recipients. All rats weighed around 200-250g and were obtained from Charles River 
(Sulzfeld, Germany). Animals were kept in standard conditions and fed standard rodent food 
and tap water ad libitum.  
 
Anaesthesia was induced by placing the animals into a sliding-top induction chamber 
(Kent Scientific, Torrington, CT, USA) connected to the anaesthetic vaporizer, delivering 
isoflurane (CP-pharma,  Burgdof, Germany) (3-4% 1L/min 0₂).  To provide analgesia during 
the procedure, 0,05mg/kg of buprenorphine hydrochloride (Buprenovet® Bayer GmbH, 
Leverkusen, Germany) were administered SC.  Once the onset of anaesthesia was ensured, 
animals were fixed on the heating table and isoflurane (1,5-2% 1L/min 0₂) was further 
delivered through a mask connected to the vaporizer.  
 
Explantation of the kidney from the donor: Preparation of the animals and of the 
surgical field was the same as previously described. The display and name of the surgical 
instruments needed for this procedure are shown in Fig.9. 
 
   




First, midline incision through the linea alba was performed from the xiphoid process 
to the pubis symphysis, having previously separated the skin from the subcutaneous tissue. 
Next, a damp swab was positioned on the thorax of the animals, and the intestines were 
carefully placed on top, wrapped into the damp swab, creating a package and making sure that 
the intestines were not subjected to torsion.  
 
After that, and with the help of cotton buds (Rotilabo®, Carl Roth GmbH, Karlsruhe, 
Germany) the descending mesocolon was dissected, allowing the descending colon to be 
placed on the left side of the abdominal cavity.  Using metal retractors (Bowman retractors, 
Fine Science Tools, Heidelberg, Germany) the operation field was made fully visible. 
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Afterwards, using cotton buds, the fat tissue covering the big abdominal vessels 
(abdominal aorta and vena cava caudalis) was carefully removed, and the left ureter was 
separated together with its surrounding fat. Next, the testicular veins were cauterised (ERBE 
cauteriser, Erbe Elektromedizin GmbH,Winsen, Germany) as well as the little vessels 
entering the vena cava caudalis approximately 1 cm cranially and 2 cm caudally of the left 
renal artery and vein (Fig. 10A and 8B ). 
 
Then, the adrenal vein was cauterised, as well as the fat tissue surrounding the left 
kidney, taking special care of preserving the integrity of the left ureter. After this step, the 
kidney was placed in the right abdomen and the vessels connecting the vena cava caudalis to 
the retroperitoneum were also cauterised and the remaining fat tissue removed, resulting in a 


























Fig. 10: A. Overview of the operation field after laparotomy. 1. Left kidney, 2. Renal vein, 3.Adrenal 
vein, 4.Descending colon, 5. Testicular veins, 6. Urinary bladder.  B. Operation field after preparation 
of the big abdominal vessels. The abdominal aorta and the v.cava caudalis are fully separated and the 
venous patch completely cleaned. 1. Abdominal aorta, 2. V. cava caudalis, 3. Renal vein, 4. Left 
ureter in periureteral fat.  
 
 
Of special importance was removing all the fat and connective tissue from the arch 
connecting the cava caudalis to the renal vein, as this constituted the venous patch for the 
venous anastomosis between donor and recipient. Once all the vessels were clean and the 
vena cava and the aorta were fully separated, the left ureter was cut, as caudally as possible, 
with its protective fat. Next, a double ligation was done around the vena cava and the aorta, 
approximately 2cm caudally to the renal artery (Fig.11). 
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The next step had to be done in less than 30 seconds in order to avoid thrombotic 
complications. An atraumatic clamp was placed on the aorta, cranially to the renal artery, 
leaving enough space to dissect the vascular stump for arterial anastomosis. Right after, the 
venous patch was cut with sharp scissors using a glass spatula, pulling carefully to the left 























Fig.11: Operation field before kidney graft retrieval. 1. Unperfused left kidney, 2. Arterial clamp, 






For flushing, 1mL of HTK solution (Histidine-tryptophan-ketoglutarate solution, 
Custiodiol®, Dr.Franz Köhler Chemie GmbH, Bensheim, Germany) at 4°C was injected 
cranially to the ligation into the aorta, using a curved 27G needle. Well performed, flushing 
resulted in fast colour change of the kidney from pink to pale brown. Afterwards, the lower 
aorta was excised under the ligation and, lastly, the upper aorta was cut right below to the 
clamp. The kidney was then kept in HTK at 4°C for 8 hours.  
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Implantation of the kidney from the donor into the recipient was performed 8 hours 
after the kidney was collected from the donor. Animal preparation and laparotomy procedure 
was the same as for the explantation. The surgical instruments needed for this procedure as 
well as their setup, is shown in Fig.12.  
 
The implantation step started with a left nephrectomy by decapsulation of the left 
kidney and hilar ligation of the renal artery and vein. Then, once the surgical field was 
completely clear, excess fat and connective tissue was removed from the surface of the 
abdominal aorta and vena cava caudalis (Fig.13A). Then, using forceps, the aorta and the 
cava were separated cranially and caudally of the recipients renal vessels in order to place 
clamps for anastomosis.  
 
Using two threads, the abdominal aorta and vena cava caudalis were moved to the 
right side in order to better visualize the vessels from the back side. All these little vessels 




Fig.12: List and display of the surgical instruments and materials needed in the implantation 
procedure 
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Next, the arterial and venous clamps were placed following the direction of blood 
circulation: cranial arterial clamp, caudal arterial clamp, caudal venous clamp, cranial venous 
clamp (Fig.13B).  Afterwards, aorta and vena cava were punctured using a 25G needle at the 
site of the latter anastomosis and dissected using microsurgery vascular scissors (Bone 
Cutting Spring Scissors, Fine Science Tools, Heidelberg, Germany). Thereafter, the vessels 
were thoroughly flushed with saline (NaCl 0,9%, Fresenius Kabi, Bad Homburg, Germany) 
until they were completely free of residual blood clots.  
 
The following step was the ventral aortic anastomosis, where the aortic stump from the donor 
was sutured to the abdominal aorta of the recipient, using a 9/0 suture (Ethilon 9/0, Ethicon, 





Fig.13:  A. Overview of the operation field after left nephrectomy and preparation of the main 
vessels.1. Abdominal aorta, 2. V. cava caudalis. B. Operation field after positioning the clamps in 
clockwise direction: 1. Arterial clamps, 2. Abdominal aorta, 3. V.cava caudalis, 4. Venous clamps.  
 
 
Afterwards, the ventral venous anastomosis was performed using a 9/0 suture (Ethilon 
9/0, Ethicon, Livingston, Scotland) and continuous stitches. For that purpose, the venous 
patch (which has a funnel shape) had to be stretched from the sides, making sure that when 
the blood would enter later it would be sufficiently open. Then, the kidney was flipped to the 
right in order to stitch the dorsal anastomosis of the venous patch. Before knotting the 
anastomosis, the open venous system had to be flushed with saline thoroughly in order to 
make sure that there was no air in it. After completion of the dorsal arterial anastomosis, the 
arterial system was flushed and the caudal aortic stump of the donor kidney was ligated using 
a 3/0 non-absorbable suture (3/0 Polyester green, SMI, Steinerberg, Belgium)(Fig.14). 
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Once both anastomoses had been performed, the clamps were removed, this time in 
anti-clockwise direction. As a result, the kidney blood flow was established and turned back 
to its physiological colour. Then, the kidney was placed and fixed in the retroperitoneum by 


























Fig.14: Operation field after aortic and venous anastomoses. 1. Unperfused kidney graft, 2. 





The final step of this procedure is the insertion of the ureter into the urinary bladder. 
For this purpose, the ureter was carefully dissected at the very distal end and freed from 
surrounding fat, then it was cut diagonally and a ligation was performed using a 10/0 suture 
(Ethilon 10/0, Ethicon, Livingston, Scotland). Next, the peritoneal cover and vesical muscle 
were separated at the apex of the urinary bladder, without destroying the mucosa. In this area 
a puncture was performed with a 25G needle. Afterwards, the needle attached to the suture 
holding the distal end of the ureter was pulled through this mucosal hole and fixed within the 
bladder by knotting the suture to the ventral bladder wall. That way the ureter was inserted 
into the bladder without tension. Then, the periureteral fat tissue was stitched to the bladder 
with 4 single stitches using a 10/0 suture (Ethilon 10/0, Ethicon, Livingston, Scotland) (Fig. 
15A and 15 B).  
 
To compensate from possible fluid loss, 2mL of NaCl 0,9% (Fresenius Kabi, Bad 
Homburg, Germany) were flushed into the abdominal cavity ; then, the abdominal wall was 
closed by layers (3/0 Surgicryl PGA, SMI, Steinerberg, Belgium) and the wound was 
disinfected with Braunol® (B.Braun, Melsungen, Germany). 
 







 Fig.15: Ureter insertion into the bladder A. Ureter after removing removing periureteral fat. B. 
The ureter is inserted into the bladder with a 10/0 needle and suture 
 
 
Lastly, animals were placed in a cage under a red light to help them recover from the 
anaesthesia.  
 








2.3. Blood and urine collection and analysis  
 
Blood samples were obtained through retrobulbar plexus puncture using haematocrit 
capillaries (Hirschmann GmbH & Co. KG, Eberstadt, Germany) and were put into EDTA-KE 
tubes (Sarstedt, Nümbrecht, Germany). Afterwards, samples were centrifuged to obtain 
plasma (Centrifuge 5415R, Eppendorf, Hamburg, Germany) for 15 min at 5000g and 4°C. 
Plasma samples were transferred into 1,5 mL Eppendorf tubes (Eppendorf, Hamburg, 
Germany) and stored at -20°C until analysis.  
 
To obtain the urine samples, animals were placed into metabolic cages, with free 
access to food and water, for 24 hours. After this time, urine production was measured, 
samples were put into 1,5 mL Eppendorf tubes and kept at -20°C until analysis.  
 
Routine plasma and urine parameters (plasma: creatinine, urea, sodium, potassium, 
calcium, total protein, cholesterol, triglycerides, phosphate and glucose; urine: creatinine, 
urea, proteinuria, sodium, potassium, phosphate, calcium and glucose) were measured using a 
cobas c311 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). Albumin content in 
urine was determined by ELISA and osmolarity was measured using an osmometer (2020 
Multi-Sample Osmometer, Advanced Instruments Inc., Norwood, MA). 
A 
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2.4. Transcutaneous assessment of renal function 
 
FITC-sinistrin (Fluorescein isothiocynate, Fresenius Kabi, Linz, Austria) was the 
fluorescent dye chosen to measure kidney function. It constitutes a suitable candidate because 
it is highly soluble in water, and fully excreted by the kidneys
124
. To obtain the final 
concentration of 40mg/mL, 1g of dye was diluted in 25 mL of NaCl 0,9% (Fresenius Kabi, 
Bad Homburg, Germany) and injected intravenously in the animals through the tail vein . 
 
The transcutaneous measurement was possible thanks to a small device attached to the 
back of the animals, constituted by two light-emitting diodes (LEDs), with an emission 
maximum for FITC-S at 470 nm and a photodiode detecting the fluorescence emitted with 
maximum sensitivity at 525 nm. The device was configured to perform a measurement every 
1757 milliseconds. The recorded data was stored in the internal memory of the device, and 
using a micro-USB cable, it was transferred into a PC. The software used to read the data and 
to obtain the clearance curves was MPD studio (Medibeacon GmbH, Mannheim, Germany). 
 
To perform the measurement, animals were placed into a sliding-top induction 
chamber (Kent Scientific, Torrington, CT, USA) connected to the anaesthetic vaporizer, 
delivering isoflurane (CP-pharma,  Burgdof, Germany) (4-5% 1L/min 0₂). The induction 
chamber was at all times on top a heating table, set at 37°C (MEDAX GmbH Neumünster, 
Germany).  
 
To make sure the signal was recorded correctly, animals were shaved from the scapula 
to the last rib, and the remaining hair was further removed using a shaving cream (Veet®, 
Reckitt Benckiser, Hull, United Kingdom). Afterwards, the device and its corresponding 
battery were attached into a double-sided adhesive patch (Lohmann GmbH&Co. KG, 
Neuwied, Germany), containing a small window where the LEDs were placed. Next, the 
patch was attached to the shaved back of the animals, and the battery was connected to the 
device, letting a background signal be measured for 4 minutes. The adhesive patch was 
further secured to the animal with an elastic net bandage (Askina 2A, Braun, Hessen, 
Germany) and a strip of adhesive tape. Then, FITC-S was injected into the tail vein (4-5 
mg/100g BW) using an intravenous cannula (26G, Terumo Deutschland GmbH, Eschborn, 
Germany). Afterwards, animals recovered from anaesthesia and were placed into a separate 
cage, allowing free movement and free access to food, but not water for at least 2 hours, 
which is the minimum time for the measurement to take place in rats (Fig 16.).  
 
When the FITC-sinistrin is injected intravenously, the fluorescent signal recorded by 
the device starts to rise until it reaches a peak. Hereafter, the signal decreases until completely 
fading, due to the excretion of the marker (Fig.17). Once the measurement was finished, the 
device was removed from the animal, and the battery disconnected.  






Fig.16: Transcutaneous measurement of renal function in conscious rats: 
a) Animals were placed into a chamber to induce mild anaesthesia using isoflurane. 
b) Device for transcutaneous measurement of renal function. Its optical part is composed by 
two LEDs on the side and one photodiode in the middle. It was placed into a double-sided 
adhesive patch with a small window to allow the signal to be recorded.  
c) The lithium battery was attached to the patch, connected to the device and the background 
signal was measured.  
d) The patch was fixed to the shaved back of the animal. 
e) The device was secured with an elastic band and leukosilk, taking care of not over 




The half- life (t½) of FITC-sinistrin was calculated by the software using a 3-compartment 
model. In a 3-compartment pharmacokinetic model, the system is divided into one central 
compartment and two peripheral compartments. Compartment one is constituted by plasma 
and tissues where the dye is distributed instantaneously, whereas peripheral compartments 
consist of tissues where the dye distribution is slower
125,126
. The use of the 3-compartment 
model allows fitting the clearance curve of animals with severely impaired kidney function, in 
contrast with the 1-compartment model, which fails to do so due to the lack of decay of the 
curve.  
 






 Fig.17: Excretion kinetics of FITC-sinistrin measured in a healthy rat 
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.  Before the injection, 
the background signal was measured. After the intravenous injection of the dye, the signal increases 





2.5. Cells and conditioned media  
 
2.5.1 Human adipose-derived mesenchymal stromal cells (hASC)  
 
hASC were isolated and cultured by Professor Karen Bieback´s group, from the 
Institute of Transfusion Medicine and Immunology (Medical Faculty Mannheim, Heidelberg 
University).  
 
Cells were isolated from human lipoaspirates obtained from healthy donors who 
underwent liposuction surgery. First, the raw lipoaspirate was thoroughly washed with sterile 
PBS to remove cellular debris and red blood cells. Then, the washed aspirates were treated 
with 0,15% w/v collagenase type I (Sigma-Aldrich, Munich, Germany), for 45-60 min at 
37°C, with gentle agitation, adding the same amount of collagenase as lipoaspirate volume 
(1:1 dilution). Inactivation of the collagenase was achieved by addition of an equal volume of 
DMEM/10% FBS (Thermo Fischer Scientific, Darmstadt, Germany) and was centrifuged 
(1200g, 10 min). The obtained stromal vascular fraction (SVF) pellet was resuspended in 
medium (DMEM low glucose, 10% FBS) and filtered through a 100µm nylon mesh filter 
(Falcon® 100 µm cell strainer, Sigma-Aldrich, Munich, Germany) to remove cellular debris. 
The filtrate was then centrifuged (1200g, 10 min) and resuspended in medium (DMEM+10% 
FBS) and plated in a T25 or T75 culture flasks (dependent of pellet size) and was incubated 
overnight at 37°C, 5% CO2. On the following day, extensive washings were performed to 
remove non-adherent cells and red blood cells, prior to media change. Cell morphology was 
constantly monitored by microscope observation. 
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After cells had started to form colonies, they were tested to assess if the criteria for 
defining multipotent MSC was met. At passage 2 cells were seeded to assess in vitro 
differentiation into osteoblasts and adipocytes during a minimum of 14 days after which a 
differentiation assay was performed. Furthermore, an extensive cell marker panel was tested 
and measure by flow cytometry to assess the expression of CD90, CD73, CD105, and lack of 




On the day the injections were scheduled, hASC were washed and suspended in PBS 
at a concentration of 1x /1mL.  
 
 
2.5.2. Human ABCB5 positive mesenchymal stromal cells (hABCB5+) 
 
ABCB5+ cells were obtained in collaboration with the company Ticeba-REHACELL 
GmbH&Co (Heidelberg, Germany).  
 
Cell isolation, culture and characterization were performed in their facility as 




Briefly, human ABCB5+ cells were obtained from healthy patients undergoing any 
medical intervention resulting in leftover skin tissue. Afterwards, skin tissue was separated 
from subcutaneous adipose tissue, disinfected, washed, dissected and enzymatically digested. 
Then, cells were centrifuged and expanded in stem cell-selecting growth media. ABCB5+ 
cells were isolated by antibody-coupled magnetic bead sorting, using a mouse-anti-human 
ABCB5 monoclonal antibody. Purity of the isolated cells was determined by flow cytometry. 
A content of 90% of ABCB5+ cells was set as optimal. After purity was checked, cells were 
cryo-preserved in liquid nitrogen. 
 
The same day the injections were scheduled, cells were thawed, washed and 
suspended in HRG solution (Ringer´s lactate solution containing 2,5% human serum albumin 
and 0,4% glucose) at  a concentration of 1x /1mL. 
 
  
2.5.3.ABCB5-derived Conditioned media (CM) 
 
Conditioned media was provided by Ticeba-REHACELL GmbH&Co (Heidelberg, 
Germany), according to their own manufacturing protocols. It was obtained by collecting the 
supernatant of the ABCB5+ cell culture.  
 
 
2.6. Organ collection  
 
At the day of right nephrectomy, the kidney was excised and weighed. Afterwards, the 
kidney poles were cut into small pieces with a disposable sterile scalpel (B.Braun, Melsungen, 
Germany), snap frozen in liquid nitrogen, and placed into CryoTube NUNC™ vials (Thermo 
Scientific, Schwerte, Germany). The frozen tissue was kept at -80°C. 
 
The remaining organ was cut in half and kept in a 4% formalin solution for at least 24 
hours. Afterwards, the tissue was processed with an automatic tissue processor (Leica 
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TP1020, Leica microsystems Nussloch GmbH, Nussloch, Germany) to be later 
embedded in paraffin.  
The same procedure was performed at the sacrifice point, when the left kidney was 
collected. All animals were sacrificed by cutting the heart under isoflurane anaesthesia (5% 
1L/min 0₂).  
 
 
2.7. Histology methods  
 
Once the tissue was processed and embedded in paraffin, it was cut (3µm thickness) 
using a rotary microtome (Richert-Jung Biocut 2030, Leica microsystems, Wetzlar, Germany) 
and left in an incubator at 37°C overnight.  
 
 
2.7.1. Haematoxylin-eosin staining (H&E) 
 
Haematoxylin-eosin is the most common staining technique used in histology for 
medical diagnosis. Haematoxylin is a deep blue-purple dye that stains nucleic acids and eosin, 
which has a pink colour, non-specifically stains proteins. Once the tissue was cut, the slides 
were placed into an autostainer (Leica ST5010 Autostainer XL, Leica microsystems Nussloch 
GmbH, Nussloch, Germany) and the staining was performed automatically, during the routine 
pathological staining.  
 
 
2.7.2. Masson-Goldner staining  
 
Masson-Goldner or Masson trichrome Goldner staining demonstrates the presence of 
connective tissue, which can be visualized by the combination of three different staining 
solutions: Azophloxine, Tungstophosphoric acid Orange G (muscle, cytoplasm and 
erythrocytes) and Light green SF (connective tissue counter-staining).  Using this technique, 
the nuclei are stained in dark brown-black, cytoplasm and muscle appear in red and 
connective tissue acquires green colour.   
 
The staining was performed by the Pathology department of the University Hospital in 
Mannheim, using an automated system during the routine pathological staining.  
  
 
2.7.3. Periodic Acid-Schiff staining (PAS) 
 
PAS staining shows mucins, basement membranes, glycogen and mycelial spores. 
When treated with periodic acid, glycols are oxidized to aldehydes. After reaction with Schiff 
reagent, the aldehydes show a purple-magenta colour. In this study, PAS staining was used to 
visualize glomerular basement membranes and tubular basement membranes, in order to 
assess glomerular and tubular abnormalities in transplanted kidneys. The staining was 
performed by the Pathology department of the University Hospital in Mannheim, using an 
automated system during the routine pathological staining. 
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 2.8. Immune histology 
 
 2.8.1. ED1staining 
 
ED1 is an antibody directed against the CD68 protein. It is used to identify 
macrophages, Kupffer cells, osteoclasts and monocytes. The ED1 antigen is expressed 




In the present study, ED1 staining was performed to quantify the 
macrophage/monocytes present in AKI and transplanted kidney sections and thus, the degree 
of inflammation in the different kidney compartments.  
 
 2.8.2. CD3 staining  
 
CD3 consists of a protein complex composed by four different chains. It is involved in 
signal transduction to the T-cell after antigen recognition.  
 
The CD3 antibody recognizes T-cells in thymus, bone marrow, peripheral lymphoid 
tissue and blood, and it also detects normal and neoplastic T-cells. It bounds to the membrane 




In the present study, CD3 staining was used to analyse the presence of T-cells in the 
kidney allografts, in order to assess T-cell mediated rejection between treated and untreated 
groups. 
 
The following protocol was followed:  
 
1. Deparaffinization and hydration: 
 Xylene (3x5 min) 
 Ethanol 100% (1min) 
 Ethanol 96% (1min) 
 Ethanol 80% (1min) 
 
2. Washing: Tris Buffered Saline (TBS) (2x5min) 
 
3. Antigen retrieval: Antigen retrieval reverses the protein modifications caused by 
fixation with formalin, optimizing the sntigen-antibody reaction. In this case, the 
antigen retrieval was produced using heat and a citrate buffer solution for 20 minutes.  
 Citrate buffer (pH 6-6,3) 
 10 min 800 Watts 
 10 min 360 Watts  
 
4. Cooling and washing: 20 min cooling at room temperature and washing in TBS 
 
5. Blocking of endogenous peroxidase: H₂O₂ (2%) in methanol (30 min.) 
 
6. Washing: TBS(2x5min)
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7. Blocking of unspecific background:  
 ED1:Horse serum 10% (20 min. in humidified chamber) 
 CD3: Goat serum 10% (20 min in humidified chamber) 
 
8. Blocking of endogenous biotin:  
 Incubation with Avidin (15 min.) 
 Incubation with Biotin (15 min.) 
 
9. Washing: TBS (2x5 min) 
 
10. Incubation with first antibody:  
 ED1: Mouse-anti-rat CD68 antibody (Linaris Biologische 
Produkte, Dossenheim, Germany) diluted 1:200 in 2% 
TBS/BSA (Overnight, 4°C) 
 CD3: Anti-CD3-antibody (Abcam, Berlin, Germany) 
diluted 1:400 in 1% goat serum (Overnight, 4°C) 
 
11. Washing: TBS (2x5 min) 
 
12. Incubation with second antibody:  
 ED1: Horse-anti-mouse antibody (Linaris Biologische 
Produkte, Dossenheim, Germany) diluted 1:200 in 2% 
TBS/BSA (45 min.)  
 CD3: Goat-anti-rabbit antibody (Linaris Biologische 
Produkte, Dossenheim, Germany) diluted 1:400 in 1% goat 
serum  (45min.) 
 
13. Washing: TBS (2x5 min) 
 
14. Incubation with avidin-biotin complex: Incubation with ABC solution (Vector 
Laboratories, Burlingame, CA/USA) (30 min.) 
 
15. Washing: TBS (2x5 min) 
 
16. Incubation with DAB solution: DAB solution (Vector Laboratories, Burlingame, 
CA/USA) (1-5 min.)  
 
17. Counterstaining: Haematoxylin (3-5 min) 
 
18. Dehydration: 
 Ethanol 80% (rinse) 
 Ethanol 96% (rinse) 
 Ethanol 100% (2x1min) 
 Xylene (3x5 min)
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2.9. Quantification of ED1 and CD3 positive cells  
 
ED1+ and CD3+ cells were quantified using a light microscope (BX51TF, Olympus 
Germany GmbH, Hamburg, Germany) coupled to a camera (XC10, Olympus Germany 
GmbH, Hamburg, Germany) and the Cell F software (Cell F 5.2, Olympus Germany GmbH, 
Hamburg, Germany).  
 
For ED1+ count, sections from both warm ischaemia models and hASC treated 
animals were taken into the analysis. Right (non-ischaemic) and left (ischaemic) kidneys were 
analysed, counting the positive cells in 20 fields each: 10 fields in the interstitium and 10 in 
the periglomerular region, using a 20x objective lens (Olympus Germany GmbH, Hamburg, 
Germany). Sections from all groups in the transplantation experiments were also analysed, 
counting the number of ED1+ cells in 10 random fields, using the same magnification.  
 
The number of positive cells was calculated by the software (expressed in positive 
cells/µm² or in % of positive cells in the selected field), after optimal intensity was manually 
selected for each field.  
 
For the CD3+ cell count, sections from transplanted kidneys (treated or untreated) 
were analysed. Ten random fields per section were chosen, and the positive cells were 
manually selected and counted using the 20x objective lens (Olympus Germany GmbH, 




2.10. Quantification of kidney fibrosis  
 
Kidney fibrosis was quantified in both warm ischaemia models, as well as in kidneys 
from hASC treated animals.  
 
Kidney sections were stained using the Masson-Goldner protocol and scanned with the 
automated slide scanner Axioscan Z1 (Carl Zeiss, Oberkochen, Germany), obtaining 
digitalized high-resolution images of the cuts (40x magnification). The images produced were 
stored in an external high storage capacity drive for further analysis. 
 
In these models, most of the fibrotic lesions are located between the cortico-medullary 
junctions and the outer cortex, and that constituted the areas of interest, which were manually 
selected using ImageJ software. Once the regions of interest were defined, their total area was 
quantified.  
 
Next, the fibrotic areas (those stained positive for collagen I deposition, thus showing 
a green colour) were manually selected for each cut. Then, the total area of these fibrotic 
selections was also quantified by the software (Fig.16 a and b). The sum of all these areas 
was performed and a percentage of fibrosis in total kidney cortex was obtained.  






 Fig.18: a. Kidney section scanned with Axioscan Z1 (40x objective lens). b. Region of interest 
(cortex) was selected and quantified. Fibrotic areas (yellow square) were manually selected and also 






2. 11. Banff classification  
 
The Banff classification was conceived in 1991 by a group of pathologists to develop 
an international scheme for standardization of criteria to diagnose renal allograft rejection, 
based on histologic analysis.  
 
The original Banff classification was divided into different categories: hyperacute 
rejection, borderline changes, acute rejection, chronic transplant nephropathy and other 
changes. Acute rejection and chronic transplant nephropathy are, in turn, classified in three 
different grades according to severity. In acute rejection, the main focus is interstitial 
infiltration, tubulitis and intimal arteritis; whereas in chronic allograft nephropathy, the 





The classification performed in the present study is a modification of the original 


















t0= No mononuclear cells in tubules or single focus of tubulitis only 
t1= Foci with 1 to 4 mononuclear cells/tubular cross section  
t2= Foci with 5 to 10 mononuclear cells/tubular cross section 








v1—Mild to moderate intimal arteritis in at least 1 arterial cross 
section. 
v2—Severe intimal arteritis with at least 25%luminal area lost in at 
least 1 arterial cross section 
v3—Transmural arteritis and/or arterial fibrinoid change and medial 







ci0—Interstitial fibrosis in up to 5% of cortical area. 
ci1—Interstitial fibrosis in 6 to 25% of cortical area (mild interstitial 
fibrosis). 
ci2—Interstitial fibrosis in 26 to 50% of cortical area (moderate 
interstitial fibrosis). 







ct0—No tubular atrophy. 
ct1—Tubular atrophy involving up to 25% of the area of cortical 
tubules. 
ct2—Tubular atrophy involving 26 to 50% of the area of cortical 
tubules. 







2.12. Exclusion criteria  
 
In both warm and cold ischaemia models a score sheet was used to determine the 
health status of all the animals in the experimental groups. Animals were checked every day 
for one week after surgery, and then every two weeks in order to assess the following criteria




Animals showing a score of three in one or more of the welfare criteria were euthanized and 




2.13. Statistical analysis  
 
The data are expressed as box plots. The middle line represents the median value of 
the respective parameter. The box delimitates the first (q1) and third (q3) quartiles of the data. 
Minimum and maximum values are depicted by the whiskers. One-way analysis of variance 
(ANOVA) followed by Tukey-Kramer test was used to evaluate differences between clinical 
chemistry parameters and histology-based quantitative parameters in all the groups through 
the different time points. In paired measurements following a parametric distribution, means 
were compared using a T-test. Survival analysis plots were generated according to Kaplan-
Meier method. Statistical significance was defined when p<0.05. All the statistical analysis 







Body weight (0-3) 
0. No weight loss 
1. <10% weight loss 
2. 10-15% weight loss 










1. Isolated soft faecal components 
2. Soft faeces 
3. Diarrhoea 
 
General behaviour (0-3) 
0. Normal 
1. Responsive 
2. Moderately irresponsive 
3. Non responsive, apathy, lethargy 





3.1. Assessment of long-term renal outcomes in a model of unilateral kidney ischaemia 
without contralateral nephrectomy  
 
3.1.1. Clinical parameters 
 
 To assess if ischaemia-induced acute kidney injury without contralateral nephrectomy 
leads to long-term kidney function impairment, baseline plasma creatinine (p-crea) and 
plasma urea (p-urea) were first measured. The left kidney was then subjected to 60 minutes of 
ischaemia (see materials and methods) and the right non ischaemic kidney was removed 170 
days after AKI induction. Animals in which the left kidney was not subjected to ischaemia 
and the right kidney was also removed at day 170 served as controls. P-crea and p-urea were 
measured at days 150, 166 and 177. Although p-crea was significantly higher in the ischaemic 
group at days 150 (0,25 ± 0,02 vs. 0,3 ± 0,02 mg/dL, Control vs. AKI; p=0,0055;) and 160 
(Control: 0,28 ± 0,02 vs. 0,31 ± 0,03mg/dL; Control vs. AKI ; p=0,0479), the values were 
within a physiologic range reported for this strain (p-Crea >0,5mg/dL; Biochemistry and 
haematology for Lewis rat colonies in North America, https://www.criver.com/products-
services/find-model/lewis-rat). At day 177, i.e. 7 days after removal of the non-ischaemic 
kidney, the mean p-Crea value in the AKI group was compatible with a mild kidney function 
impairment and significantly higher than that of the controls (0,38 ± 0,02 vs. 0,66 ± 0,29 
mg/dL, Control vs. AKI; p=0,0341) (Fig.19A). P-urea values showed a similar pattern as 
observed for p-crea. Statistical significant differences between the control and AKI group 
were achieved at days 166 (31,38 ± 1,9  vs. 35,38 ± 2,8 mg/dL, Control vs. AKI; p=0,012) 
and 177 (45,6 ±4,89 vs. 77,9 ± 37,55 mg/dL, Control vs. AKI; p=0,0446)(Fig.19B). 
 
Like p-crea and p-urea, also proteinuria was increased in the AKI as compared to the 
control group. Significance between both groups was reached at day 150 (14,45 ± 2,52 vs. 
27,91 ± 14,51 mg/24h, Control vs. AKI p=0,0362) and at day 177 (16,492 ± 3,78 vs. 33,11 
±15,29 mg/24h, Control vs. AKI p=0,0139)(Fig.19C). 
 
 FITC-S clearance was used to assess impairment of glomerular filtration rate. No 
difference in half-life time (t1/2) of FITC-S between the control and AKI groups were found at 
days 150 (27,42 ± 3,2 vs. 28,8 ± 4,7 min, control vs. AKI) and 166 ( 23,75 ± 4,1 vs. 28,1 ± 
6,4 min, control vs. AKI). Importantly, none of the values were in a pathological range (i.e. 
t1/2> 40min
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) at these time-points. In contrast, 7 days after removal of the non-ischaemic 
kidney a significant difference between the control and AKI group was observe reaching 
pathological levels (27,7 ± 5,9 vs. 61,91 ± 31,38 min, Control vs. AKI p=0,0244) (Fig.20). 
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Fig.19: Kidney function parameters in AKI-induced (n=6) 
vs control rats (n=6) in late stages of post-ischaemic injury. 
Plasma creatinine (A), plasma urea (B) as well as 
proteinuria (C) (normalized   according to the volume of 
urine produced in 24 hours) are depicted. The results are 
displayed as boxplots, with the median (middle line), upper 
and lower quartile (interquartile range, IQR) and whiskers 
(1,5*IQR). Statistical significance is defined when p<0,05, 
after mean values of each parameter in AKI vs. control 
groups were compared using a t-test. *p<0,05, **p<0,01. 
 























Fig.20: Half-life for FITC-S clearance in AKI-induced (n=6) vs. control group (n=6) remained similar 
in both groups until the contralateral kidney was removed in the AKI group, when a pathological 
increase in the t1/2 of FITC-S was observed. The results are displayed as boxplots, with the median 
(middle line), upper and lower quartile (interquartile range, IQR) and whiskers (1,5*IQR). 
Significance between groups was assessed by comparing the means of this parameter in both groups 







As a summary, values of the main kidney function parameters assessed throughout the 








Table 1: Kidney function parameters assessed, namely: p-crea (mg/dL), p-urea (mg/dL), proteinuria (mg/24h) and t1/2 FITC-S (min), in control 
(n=6) and AKI groups (n=6), expressed as mean ± SD. Values shown in red are within the pathologic range for the Lewis strain. Statistical 
significance between AKI vs. control group was defined when p<0,05, by means of t-test. (ns: not statistically significant) 
 
 
 Baseline Day 150 Day 166 Day 177 
Control AKI p 
value 
Control AKI p 
value 
Control AKI p 
value 




0,15±0,02 0,22±0,01 ns 0,27±0,02 0,3±0,02 0,005 0,27±0,03 0,31±0,03 0,04 0,38±0,02 0,66±0,29 0,03 
P-urea  
 
33,7±3,6 31±2,7 ns 27,5±1,2 40,6±7 0,002 31,4±3,6 35,4±2,9 ns 45,6±4,9 77,9±37,5 0,026 
Proteinuria 
 
15±1,8 17,2±3,4 ns 14,4±2,5 27,9±14,5 0,362 17,6±3,3 30±15,2 ns 16,5±3,7 35,4±15,3 0,013 
t1/2 FITC-S 
 
24,1±3,4 21,5±3,6 ns 27,4±3,2 27,9±4,4 ns 23,3±4,2 28,2±7,1 ns 27,7±5,9 61,9±32,4 0,024 
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3.1.2. Macroscopic and histological changes  
 
In order to assess how ischaemic injury affects kidney morphology macroscopically, 
both post-ischaemic and non-ischaemic kidneys were weighed. The weight of the non-
ischaemic kidneys in the AKI-induced animals was significantly higher than the non-
ischaemic kidney of the control animals (0,39 ± 0,04 vs. 0,58 ± 0,08 g/100g BW, Control vs. 
AKI p=0,0001). In contrast, the weight of the left (ischaemic) kidneys in the AKI group was 
significantly lower than the left (non-ischaemic) kidneys in the control group (0,5 ± 0,027 vs. 
0,35 ± 0,03g/100g BW, control vs. AKI; p<0,001) (Fig.21A). In all cases the post-ischaemic 
kidneys showed an irregular and wrinkly surface and in about 33% of the animals a dramatic 
decrease in kidney size was evident. Furthermore, cyst formation occurred in 50% of the 
animals in the AKI group and was only observed in the left ischaemic - but not in the right 




































Fig.21: Macroscopic changes in the ischaemic and non-ischaemic contralateral kidney. (A) The right 
non-ischaemic kidneys in both groups as well as the left ischaemic kidney and left non ischaemic 
kidney 
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in the AKI (n=6) and control (n=6) group respectively were weighed. The results are displayed as 
boxplots, with the median (middle line), upper and lower quartile (interquartile range, IQR) and 
whiskers (1,5*IQR). Statistical significance is defined when p<0,05, after means in AKI vs. control 
groups were compared using a t-test. *p<0,05, **p<0,01, ***p<0,001. (B) Macroscopic findings in the 
post-ischaemic kidneys in the AKI-group. Several cysts of different sizes (arrows) are visible 
throughout the kidney surface (picture to the left). Severe size reduction and wrinkling together with 




Microscopic analysis was next performed using light microscopy (general histology, 
haematoxylin-eosin (HE) staining), immune histology (for macrophage infiltration using ED1 
antibody) and Masson-Goldner staining (fibrosis). 
 
Haematoxylin-eosin staining in the post-ischaemic kidneys revealed lesions typically seen 
after ischaemic injury mostly gathered in the outer cortex. These include tubular dilations and 
tubular atrophy with foci of interstitial infiltration (Fig 22 A and B). Although cyst formation 
is not a classic histopathological feature of ischaemic injury, but rather of progressive renal 









Fig 22: Renal histology of post-ischaemic 
kidneys in the AKI group. Sections were 
process as described in materials and 
methods. The main histopathological features 
observed in this model are: (A, B) Areas of 
tubular dilation (TD) and tubular atrophy 
(TA),together with the presence of 
inflammatory cells (IN) in areas of interstitial 
fibrosis (IF) (C) Cysts of different sizes (Cy) 
in the outer cortex next to areas of interstitial 
infiltration (IN)(H-E, 100X). 
 





Although the right non –ischaemic kidneys in the AKI group presented with a significantly 
increased weight, no signs of histo-morphologic abnormalities or signs of ongoing 
inflammation or scarring were observed (Fig. 23 A and B ). Renal histology of these animals 







 Fig.23: (A, B) Sections of non-ischaemic kidneys of AKI-induced animals show no 
glomerular or tubular abnormalities 180 days after AKI induction. (C, D) Similar findings are 





Immune histology using ED1 antibody was performed to assess the degree of 
macrophage infiltration. The post-ischaemic kidneys showed significantly increased numbers 
of ED1+ macrophages compared to the control group (162,38 ± 47,39 vs. 7105 ± 4940,45 
cells/µm² control vs. AKI; p= 0,0092) (Fig. 24A). ED1+ cells were found most predominantly 
in the outer cortex and cortico-medullary junction, in areas of extensive interstitial fibrosis 
(Fig. 24 B and E), as well as in areas of tubular atrophy (Fig. 24C) and dilation (Fig. 24D). 
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ED1+ macrophages were seldom in sections of the right non-ischaemic kidneys from 





Fig.24 (A): AKI induction leads to a significant increase in ED1+ cells in the post-ischaemic kidney 
(AKI, n=6), compared to control group (n=6). The results are expressed in box plots. Statistical 
significance is defined when p<0,05, after mean values in AKI vs. control groups were compared
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using a t-test. *p<0,05, **p<0,01, ***p<0,001. (B) Macrophage infiltrate in areas of interstitial 
fibrosis (ED1, 100X), (C) ED1+ cells surrounding atrophic tubules (ED1, 200X), (D) ED1+ cells in 
areas of tubular dilation (ED1, 100X), (E) Large ED1+ infiltrate in an area of severe interstitial 




Masson-Goldner staining was used for the assessment of kidney fibrosis, a 
characteristic of progressive chronic kidney disease. Post- ischaemic kidneys in the AKI 
group showed areas of interstitial fibrosis scattered mostly through the outer cortex (Fig.25 
A). Interstitial fibrosis was accompanied by tubular atrophy, characterized by thickening of 
the basement membrane causing reduction of the tubular lumen. This feature, together with 
the presence of hyaline casts evidenced tubular injury (Fig.25B). Moreover, some of the AKI-
induced animals presented different sized cysts surrounded by large amounts of connective 
tissue and atrophic tubules (Fig. 25C). Glomerular abnormalities, e.g. enlargement of the 
Bowman space, were also observed in the animals displaying the severest degrees of tissue 
fibrosis (Fig. 25D). Kidney fibrosis was quantified on the basis of connective tissue 
deposition in the renal cortex as described in section 2.10. The percentage of connective tissue 
deposition in the AKI group was significantly higher than in the control group, where the 
presence of pathologic deposition of connective tissue was almost non-existent (0,02 ± 0,008 
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Fig.25: Masson-Goldner staining demonstrates the presence of connective tissue (green) in the post-
ischaemic kidneys of AKI-induced animals: (A) Areas of interstitial fibrosis are scattered through the 
outer cortex (M-G, 40X), (B) Severe degree of interstitial fibrosis (IF) is observed accompanied with 
tubular atrophy (TA) and hyaline casts (HC)(M-G, 100X), (C) Cysts of different sizes (Cy) are 
observed in the outer cortex, surrounded by areas of interstitial fibrosis and tubular atrophy (M-G, 
100X), (D) Glomerular abnormalities like enlargement of the Bowman space (arrow) due the presence 






















Fig.26: AKI-induced animals (n=6) show significantly higher percentage of fibrosis in the cortex of 
the post-ischaemic kidney compared to control animals (n=6) when assessed 180 days after initial 
injury. The results are displayed as boxplots, with the median (middle line), upper and lower quartile 
(interquartile range, IQR) and whiskers (1,5*IQR). Statistical significance is defined when p<0,05, 







3.2. Assessment of long-term renal outcomes using two different models of 
ischaemia-induced acute kidney injury 
 
 
3.2.1. Clinical parameters 
 
Changes in the acute phase: To better understand the long-term effects of ischaemia 
induced AKI on kidney function, we first assessed kidney function in the acute phase in two 
models of AKI. To this end, plasma creatinine and plasma urea were determined before, and 1 
and 3 days after the onset of AKI. Two groups of rats were studied, i.e. rats in which the 
contralateral kidney was removed immediately after AKI induction (AKI Nx0) and rats in 
which the contralateral kidney was maintained until day 170 (AKI Nx170). 
 




One day after AKI-induction, animals in the AKI Nx0 group displayed a significant 
rise in p-crea as compared to animals in the AKI Nx170 group (2,7 ± 0,37 vs. 0,41 ± 0,05 
mg/dL AKI Nx0 vs. AKI Nx170; p<0,001). Three days after the onset of AKI p-crea 
remained in a pathologic range in animals of the former group, while p-crea of animals in the 
AKI Nx170 was still in a normal range (2,89 ±1,39 vs. 0,34 ± 0,03 mg/dL, AKI Nx0 vs. AKI 
Nx170; p=0,0003) (Fig.27A). Similar as observed for p-crea, p-urea increased only in animals 
of the AKI Nx0 group (at day 1: 248,62 ± 22,37 vs. 40,31 ± 5,6 mg/dL, AKI Nx0 vs. AKI 
Nx170; p<0,001; at day 3: 407,02 ± 148,08 vs. 45,81 ± 5,46 mg/dL, AKI Nx0 vs. AKI 
Nx170; p<0,001) )(Fig.27B) Hence, only animals of the AKI Nx0 group displayed severe 
kidney function impairment in the acute phase. This was in line with an increased t1/2 for 
FITC-S clearance in these animals (at day 1: 682,87 ± 528,72 vs. 31,78 ± 12,95 min, AKI 
Nx0 vs. AKI Nx170; p=0,019; at day 3: 189,69 ± 172,26 vs. 34,68 ± 7,26 min, AKI Nx0 vs. 
AKI Nx170; p=0,019)(Fig.27C).  Renal function parameters in the AKI Nx0 group returned 
to baseline values 7 days after AKI induction in 85% of the animals. Due to the severity of 
this model, 15% mortality was observed in the AKI Nx0 group. In contrast, in the AKI Nx170 
group animals showed no kidney function deterioration at any of the time points tested in the 
acute phase, and, accordingly 100% survival was found.   
 
 
Changes in the chronic phase: At later stages, p-crea increased to a similar degree in 
both ischaemic groups and at all points was slightly higher compared to the no-AKI controls. 
Except for day 150 in the AKI Nx0 the differences did not reach statistical significance. Since 
in the AKI Nx170 group the contralateral non-ischaemic kidney was not removed until day 
170, kidney function deterioration of the ischaemic kidney could not be assessed. One week 
after removal of the contralateral kidney p-crea increased to pathological levels and was 
significantly higher compared to the AKI Nx0 and control groups. (0,66 ± 0,29 vs. 0,35 ±0,04 
mg/dL, AKI Nx170 vs. AKI Nx0; p=0,0084) (Fig.28A). Likewise p-urea increased much 
stronger in the AKI Nx170 group at day 177 (77,9 ± 37,55 vs. 49,47 ± 8,97 mg/dL, AKI 
Nx170 vs. AKI Nx0, p=0,05), albeit that significant differences between the control group 
were also found for the AKI Nx0 group at earlier time-points (day 150: 47,7 ± 8,67 vs. 34,84 
±3,09 mg/dL, AKI Nx0 vs. Control, p=0,013; day 166: 46,52 ±7,18 vs. 31,38 ± 1,96 mg/dL, 
AKI Nx0 vs. Control, p=0,0002)(Fig.28B). At early time-points the t1/2 of FITC-S clearance 
was significantly increased only in the AKI Nx0 group (day 150: 44,46 ± 10,07 vs. 27,42 
±3,27 min.,  AKI Nx0 vs. Control; p=0,0019; day 166: 41,1 ±7,16 vs. 23,37 ± 4,16 min, AKI 
Nx0 vs. Control, p=0,0018), while in the AKI Nx170 group significance was only reached 
one week after removal of the contralateral kidney (61,91 ± 32,3 vs. 27,78 ± 5,99 min, AKI 
Nx170 vs. Control, p=0,024) (Fig.28C). 
 
 
3.2.2. Histopathology findings  
 
 Haematoxylin-eosin staining AKI Nx0 kidney sections were compatible with 
ischaemic injury and similar to those found in AKI Nx170 post-ischaemic kidneys. However, 
the location as well as the severity of some lesions, e.g. tubular dilations hyaline casts where 
different. In AKI Nx0 animals, large areas of severe tubular dilation were found in the inner 
cortex of the kidney, while in AKI Nx170 animals sections tubular dilation were more 
abundant in the outer cortex. In the former groups of animals, the number and severity of the 
tubular dilations was much higher than in the latter group of animals. This was accompanied 
by hyaline casts in the AKI Nx0 animals (Fig.29).  
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Fig 27: Kidney function parameters in the acute phase. Two 
groups of rats were studied, i.e. rats in which the 
contralateral kidney was removed immediately after AKI 
induction (AKI Nx0, n=9) and rats in which the 
contralateral kidney was maintained until day 170 (AKI 
Nx170, n=8). Plasma creatinine (A) and plasma urea (B) as 
well as t1/2 of FITC-S clearance (C) are depicted. The 
results are displayed as boxplots, with the median (middle 
line), upper and lower quartile (interquartile range, IQR) 
and whiskers (1,5*IQR). Statistical significance is defined 
when p<0,05, after mean values of each parameter in AKI 
vs. control groups were compared using a t-test. *p<0,05, 
**p<0,01, ***p<0,001. 
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Fig 28: Kidney function parameters in the chronic phase. Two 
AKI groups were studied: i.e. rats in which the contralateral 
kidney was removed immediately after AKI induction (AKI 
Nx0, n=9) and rats in which the contralateral kidney was 
maintained until day 170 (AKI Nx170, n=8). Animals where no 
AKI was induced, but contralateral kidney was removed at day 
170 served as controls (n=6). Plasma creatinine (A) and plasma 
urea (B) as well as t1/2 of FITC-S clearance (C) are shown. The 
results are displayed as boxplots, with the median (middle line), 
upper and lower quartile (interquartile range, IQR) and whiskers 
(1,5*IQR) Statistical significance is defined when p<0,05, after 
ANOVA followed by Tukey-Kramer test. *p<0,05, **p<0,01, 
***p<0,001. 
 





 Fig.29: Post-ischaemic kidney sections of AKI Nx0 (A) and AKI Nx170 animals (B), 180 
days after AKI induction. AKI Nx0 rats present areas of severe tubular dilation (TD) scattered through 
the inner cortex, accompanied with the presence of hyaline casts (asterisk) (H-E, 100X); whereas AKI 
Nx170 animals show scattered foci of interstitial fibrosis (IF) and tubular atrophy (TA), present 





Immune histology of the post-ischaemic kidneys showed significantly increased 
number of ED1+ macrophages in both groups as compared to the control group (5370 ± 3431 
vs. 162 ±47 cells/µm², AKI Nx0 vs. Control, p=0,033; 7105 ± 4940 vs. 162 ±47 
cells/µm²:AKI Nx170 vs. Control, p=0,033) (Fig.30A). Although the mean number of 
infiltrated ED1+ cells was larger in the AKI Nx170 group the difference did not reach 
statistical significance. Scattered foci of ED1+inflammatory cells were found around the 
glomerulus or in areas of tubular dilation in the AKI Nx0 group of animals (Fig.30B ), 
whereas ED1+ macrophages were mostly located within the fibrotic areas or surrounding the 




 Masson-Goldner staining revealed more severe kidney fibrosis in AKI Nx170 post-
ischaemic kidneys (Fig. 31 A and B), with larger areas of interstitial fibrosis and tubular 
atrophy located in the outer cortex. In contrast, AKI Nx0 post-ischaemic kidney sections 
showed smaller areas of interstitial fibrosis, much more scattered and predominantly in the 
inner cortex (Fig. 31 C and D). Quantification of fibrosis demonstrated that the degree of 
fibrosis for each of the AKI groups was only significant when compared to controls, but not 
was significant between both AKI groups (0,02 ± 0,008 vs. 0,375 ± 0,18% control vs. AKI 











 Fig. 30: (A) ED1+ cell infiltration (positivity/µm²) was assessed in sections of the post-
ischaemic kidneys in Control (n=7), AKI Nx0 (n=6) and AKI Nx170 (n=6) groups. Quantification of 
ED1+ cells was performed by quantitative morphometric analysis, and showed that AKI induction in 
either conditions leads to a significant increase in ED1+ macrophages compared to the control group, 
albeit no significant differences amongst both ischaemic groups was observed. The results are 
displayed as boxplots, with the median (middle line), upper and lower quartile (interquartile range, 
IQR) and whiskers (1,5*IQR). Statistical significance is defined when p<0,05, after ANOVA followed 
by Tukey-Kramer test. *p<0,05, **p<0,01. (B) ED1 staining in the post-ischaemic kidney of AKI Nx0 
animal shows scattered foci of ED1+ macrophages around the glomerulus (arrow) and in areas of 
tubular atrophy (asterisk), (C) ED1 staining in the post-ischaemic kidney of Nx170 animal  
demonstrates the presence of ED1+ macrophages in in areas of interstitial fibrosis and tubular atrophy 
of the outer cortex (ED1, 100X).  




 Fig.31: (A) Quantification of kidney fibrosis using Masson-Goldner staining revealed a higher 
percentage of connective tissue deposition in the cortex of both AKI-induced groups  (AKI Nx0 n=7, 
AKI Nx170 n=6) compared to the control group (n=6). AKI Nx170 presented higher degree of fibrosis 
compared to AKI Nx0, although no statistical significance was found among the ischaemia-induced 
groups .The results are displayed as boxplots. Statistical significance is defined when p<0,05, after 
ANOVA followed by Tukey-Kramer test. **p<0,01, ***p<0,001. AKI Nx170 animals (B and C)  
show higher severity of interstitial fibrosis and tubular atrophy gathered in the outer cortex (MG, 40X-
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100X, respectively); on the other hand, AKI Nx0 animals  (D and E) present milder degree of 
interstitial fibrosis and tubular atrophy, with small, scattered lesions in the inner cortex (MG, 40X-




3.3. Assessment of the therapeutic efficacy of human adipose-derived 
mesenchymal stromal cells (hASC) in an ischaemia-induced AKI model  
  
3.3.1. Clinical parameters  
 
In order to assess whether hASC treatment is able to ameliorate long-term kidney 
function deterioration, animals were subjected to ischaemia induced AKI without immediate 
removal of the non-ischaemic contralateral kidney. Renal function parameters p-crea and p-
urea were measured at similar time intervals as described in sections 3.2 and 3.1.  
 
In animals treated with hASC p-crea levels were at all post-ischaemic time points 
slightly lower compared to animals that were vehicle treated (NaCl 0,9%) or compared to 
animals that were not subjected to AKI.  Statistical significance was found at day 150 (0,3 
±0,02 vs. 0,27 ± 0,02 mg/dL, AKI vs. AKI+hASC; p=0,025). Due to the presence of the 
contralateral kidney all p-crea values remained in the normal range. One week after removal 
of the contralateral kidney the mean p-crea level became pathologic only in the vehicle treated 
animals but not in animals that received hASC, where treatment was able to significantly 
reduce p-crea to a non-pathologic range (0,66 ± 0,29 vs. 0,49 ± 0,06 mg/dL, AKI vs. 
AKI+hASC; p=0,049) (Fig.32A). Compared to vehicle treated AKI animals, hASC treatment 
also decreased p-urea values at all post-ischaemic time points with statistical significance 
observed at day 150 (40,65 ± 7,09 vs. 30,72 ± 2,21 mg/dL, AKI vs. AKI+hASC; p=0,0003) 
and day 177 (77,9 ± 37,55 vs. 49,65 ± 6,8 mg/dL AKI vs. AKI+hASC; p=0,032) (Fig.32B).  
 
 
3.3.2. Renal histology  
 
Haematoxylin-eosin staining renal sections did not differ outstandingly between 
vehicle and hASC-treated AKI  induced animals, presenting a similar degree of tubular 
dilation mostly found in the outer cortex, (Fig. 33 A and B) as well as comparable amount of 
hyaline cast formation. 
 
Immune histology using ED1 antibody was performed to assess if inhibition of 
macrophage infiltration might be held accountable for the beneficial effect of hASC. Indeed 
hASC treatment significantly decreased the infiltration of ED1+ macrophages as compared to 
vehicle treated animals (7105 ± 4940 vs. 828 ± 398 cells/ µm², vehicle vs. hASC; 
p=0,0001)(Fig.34). In vehicle treated animals, macrophage infiltration was particularly 
observed in the outer cortex, in areas of tubular atrophy and interstitial fibrosis (Fig.35A), and 
less frequently in glomeruli of the post-ischaemic kidneys (Fig.35B). In hASC treated animals 
a few scattered foci of macrophage infiltration mostly surrounding the glomeruli or between 
the tubuli were visible (Fig. 35 C and D) 
 





Fig.32: Kidney function parameters assessed to determine the efficacy of hASC treatment in AKI-induced animals. (A) Plasma creatinine is decreased 
at all post-ischaemic time points in cell-treated animals (n=10) compared to vehicle treated ones (n=6). After contralateral nephrectomy (day 177), a pathologic 
increase in p-crea is observed in the vehicle treated group, which is able to be significantly reduced by cell-treatment. A same trend is observed for plasma urea 
(B) where hASC treated animals also present lower values compared to vehicle-treated at all post-ischaemic time points. Likewise, after the contralateral 
nephrectomy is performed, a pathologic increase in p-urea in vehicle-treated animals is significantly reduced to non-pathologic levels in hASC-treated. The 
results are displayed as boxplots, with the median (middle line), upper and lower quartile (interquartile range, IQR) and whiskers (1,5*IQR). Statistical 
significance is defined when p<0,05, after ANOVA followed by Tukey-Kramer test. *p<0,05, ***p<0,001 





 Fig. 33: Hematoxylin-eosin stained sections of the post-ischaemic kidneys of vehicle- treated 
(A) and hASC- treated (B) AKI-induced animals showed a comparable degree and pattern of tubular 



























Fig.34: ED1+ cell infiltration (positivity/µm²) was assessed in control (n=8), AKI (vehicle-
treated, n=6) and AKI+hASC (n=10) groups by a quantitative morphometric analysis, showing that 
hASC treatment is able to highly significantly reduce the number of ED1 positive macrophages in the 
post-ischaemic kidneys compared to the AKI-vehicle treated group.  The results are displayed as 
boxplots, with the median (middle line), upper and lower quartile (interquartile range, IQR) and 
whiskers (1,5*IQR). Statistical significance is defined when p<0,05, after ANOVA followed by 











 Fig.35: ED1 staining of post-ischaemic kidney sections of vehicle-treated and hASC-treated 
group. Vehicle-treated group presents areas of extensive ED1+ infiltration (asterisks) in areas of 
tubular atrophy and interstitial fibrosis (A and B); whereas hASC-treated animals (C and D) show 






Masson-Goldner staining revealed a subtle reduction of tissue fibrosis in the hASC 
treated animals (Fig.36A and B), albeit that the difference in the extent of fibrosis did not 
reach statistical significance (0,37 ± 0,189 vs. 0,271 ± 0,1 %; vehicle vs. hASC; p>0,05 
(Fig.36C). 







3.4. Therapeutic efficacy of human ABCB5+ and its derived CM in a chronic 
kidney allograft rejection model  
 
3.4.1. Animal general condition  
 
Since hASC seem to be effective in the aforementioned AKI model, but the model 
itself did not result in severe renal function impairment, we questioned if the beneficial effect 
of MSC would still be found in a model that leads to severe chronic renal function 
deterioration.  
 
Within the first week of transplantation animals were evaluated every day and 
thereafter every other week until completion of the experiment at day 98 after kidney 
transplantation. The evaluation consisted of assessing animals’ weight and behaviour. 
Fig.36: Kidney fibrosis shown with Masson-
Goldner staining in post-ischaemic kidneys of 
AKI (A) and AKI+hASC (B) groups 180 days 
after injury. Similar location pattern as well as 
degree of interstitial fibrosis is observed in 
both groups. (C) Quantification of kidney 
fibrosis revealed a lesser degree of fibrosis in 
the cortex of hASC-treated animals (n=6) 
compared to the vehicle-treated group (n=6), 
although no statistical significance was found 
between the two ischaemic groups. The results 
are displayed as boxplots, with the median 
(middle line), upper and lower quartile 
(interquartile range, IQR) and whiskers 
(1,5*IQR). Statistical significance is defined 
when p<0,05, after ANOVA followed by 
Tukey-Kramer test. **p<0,01, ***p<0,001 
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Animals showing signs of lethargy, unresponsiveness to external stimuli, or signs of 
neurologic disorders were euthanized. These signs were, in most cases, found soon after 
transplantation, and were the result of hydronephrosis or paralytic ileus. Neurologic signs 
were found in a few cases at later time points possibly as a result of increased p-crea/p-urea 
values due to failure of graft function. If none of the above mentioned complications occurred 
leading to pre-defined euthanasia, a 100 % of the animals (n=7) survived. For the treated 
study arms this was 83,3 % (n=7) and 77,7 % (n=5) in the CM and ABCB5 cell-treated 




3.4.2. Clinical parameters  
 
 In all three groups and at all time points tested, plasma creatinine values were within a 
pathologic range, reaching the highest values at day 84 and day 98 after transplantation 
(Fig.37A). At these two last time points, ABCB5 cell-treated animals showed higher p-crea 
values compared to CM-treated and controls animals (day 84: 1,09 ± 0,47 vs. 0,8±0,26 mg/dL 
ABCB5 vs. control, p=0,27 and 1,09 ± 0,47 vs 0,81± 0,2 mg/dL ABCB5 vs CM-treated, 
p=0,35; day 98: 1,34 ± 0,76 vs. 0,82 ± 0,35 mg/dL ABCB5 vs. control, p=0,19 and 1,34 ± 
0,76 vs. 0,89 ± 0,26 mg/dL ABCB5 vs. CM-treated, p=0,35). P-crea in CM-treated animals 
showed a similar progression as in the control group. Like p-crea, p-urea was pathologically 
increased at all time points tested in the three experimental groups, reaching the highest 
values at day 28  (114,88 ± 37,5 vs. 98,14± 28,53 mg/dL ABCB5 vs. control; p=0,54 , 
92,26±82,26 vs. 98,14±28,53 mg/dL CM-treated vs. control, p=0,93 and 114,88 ± 37,5 vs. 
92,26 ± 82,26 mg/dL ABCB5 vs. CM-treated, p=0,4) and at days 84 (120,14 ± 45,43 vs. 
95,25±30,19 mg/dL ABCB5 vs. control p=0,34; 95,25 ± 30,19 vs. 95,25±30,19 mg/dL, 
p=0,99 and 120,14 ± 45,43 vs. 92,26 ± 82,26 mg/dL ABCB5 vs.CM-treated , p=0,46)  and 98 
after kidney transplantation (156,25 ±106,7 vs. 98,24 ±37,02 mg/dL ABCB5 vs. control 
p=0,28; 101,64 ± 7,96 vs. 98,24 ± 37,02 mg/dL CM-treated vs. control, p= 0,99 and 156,25 
±106,7 vs. 98,24 ± 37,02 mg/dL ABCB5 vs. CM-treated, p=0,39) . P-urea displayed a similar 
hierarchy as p-crea, i.e. being the highest in the ABCB5 cell-treated animals and no difference 
between CM treated and vehicle treated control animals (Fig.37B). The increased p-crea and 
p-urea values were accompanied by an increased proteinuria, which was also much higher in 
the ABCB5 cell-treated group compared to the CM-treated and control groups, predominantly 
at day 98 after transplantation (223,58 ± 121,3 vs. 132,31±61 mg/24h ABCB5 vs. control, 
p=0,15;  223,58 ± 121,3 vs. 192,7 ± 54,57 mg/24h ABCB5 vs. CM-treated p=0,82 )(Fig.37C).  
Polyuria, i.e. urine volume >3,3mL/100g BW/24h, was observed in all groups and was neither 
affected by the ABCB5 cell - nor by the CM treatment (Fig.38A). Polyuria was accompanied 
by low osmolarity (osmolarity ≤1400 mosmol/L), which was similar in all the three groups 
(Fig.38B) Transcutaneous FITC-S clearance was assessed one day before the animals were 
sacrificed. In the ABCB5-treated animals, the t1/2 for clearance of the dye was longer 
compared to controls (99,37± 85,29 vs.77,41 ± 34,84 min; ABCB5 vs. control; p=0,86) and 
slightly longer compared to CM-treated animals (99,37± 85,29 vs. 97,1 ± 85,26 min; p=0,99). 
For all three group t1/2 values for FITC-S clearance were compatible with severely impaired 















Fig.37: Kidney function parameters assessed to determine 
efficacy of ABCB5+ cells and ABCB5-derived CM treatment 
in transplanted animals (A) Plasma creatinine was 
pathologically increased in the three groups at all time points, 
particularly in ABCB5+ treated animals (n=7). Control (n=7) 
and CM-treated group (n=5) showed similar progression 
throughout the experimental time. (B) Plasma urea showed a 
similar trend, being the highest values found in ABCB5-
treated animals. Likewise, no difference between CM-treated 
and control animals were observed (C) Proteinuria values 
were within the pathologic range in the three groups at all time 
points, mostly in the ABCB5 treated group at endpoint (day 
98), compared to CM-treated and control group. The results 
are displayed as boxplots, with the median (middle line), 
upper and lower quartile (interquartile range, IQR) and 
whiskers (1,5*IQR) 




 Fig.38: (A) Urine output in 24 hours was measured in control (n=7), ABCB5+ (n=7) and CM-treated animals (n=5) at different time points after kidney 
transplantation. Animals in all the groups presented polyuria, which was not affected by either of the treatments.  This highly polyuric state was associated with 
low urine osmolarity (B), with similar values among the groups. The results are displayed as boxplots, with the median (middle line), upper and lower quartile 
(interquartile range, IQR) and whiskers (1,5*IQR). 
 


















Fig.39: Transcutaneous FITC-S clearance was assessed in control (n=6), ABCB5+ (n=4) and CM-
treated (n=4) animals one day before sacrifice (day 97 after transplantation). ABCB5+ treated animals 
presented longer t1/2 for clearance of the dye compared to controls and slightly longer compared to 
CM-treated group. Clearance values found in all three groups were compatible with highly impaired 
kidney function. The results are displayed as boxplots, with the median (middle line), upper and lower 









3.4.3. Renal histology  
 
Chronic renal allograft rejection in the Fischer to Lewis model is mostly accompanied 
by features of T-cell mediated rejection, with its typical hallmark of tubulitis (Fig.40A); 
endarteritis and in severe cases, transplant vasculopathy with the presence of intimal 
endarteritis and intimal fibrosis (Fig.40B). In some cases, features characteristic for antibody-
mediated rejection can be observed. This is mostly manifested as glomerular abnormalities, 
like thickening of the glomerular basement membrane, dilation of the glomerular capillaries 
and glomerulitis (Fig.40C). In addition, extensive areas of tubular dilation are observed, as a 
result of ischaemia-reperfusion injury (Fig.40A). Interstitial fibrosis and tubular atrophy are 
also very important features in this model, and they are mostly the result of the sustained 
cellular and humoral immune responses through a long period of time (Fig.40A). 




 To assess the differences in overall inflammation in the kidney grafts between groups, 
ED1 staining was performed, and the number of positive cells was counted. Quantification 
showed that ABCB5-treated animals presented an increased number of ED1+ cells (17421 ± 
5019 vs. 11628 ± 6133 cells/ µm², ABCB5-treated vs. control; p=0,11). On the other hand, 
CM-treated animals showed less ED1+ macrophages than cell-treated (14451 ± 3751 vs. 
17421 ± 5019 cells/ µm² CM-treated vs. ABCB5-treated; p= 0,6), but not less than the control 
group (14451 ± 3751 vs. 11628 ± 6133 cells/ µm², CM-treated vs. control; p=0,62) (Fig.41). 
 
 
Fig.40: Main histopathological features of the Fischer-
Lewis model of allograft rejection (A) Areas of 
tubular dilation are observed as a result of ischaemia-
reperfusion injury (blue square), surrounded by 
interstitial fibrosis and atrophic tubules (IF-TA). In 
the most severe cases, transplant vasculopathy (yellow 
square) can be observed, which is characterized by 
endarteritis and intimal fibrosis that leads to occlusion 
of the vessels (H-E, 40X). (B) Tubulitis is one of the 
main features of T-cell mediated rejection. 
Mononuclear cells (arrows) are present between the 
tubular epithelial cells (PAS, 200X). (C) Some lesions 
associated to antibody-mediated rejection can be 
observed, like dilated glomerular capillaries and 
swollen endothelial cells (arrows) (PAS, 100X). 
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Apart from ED1+ macrophages also CD3+ T-cells infiltrate into the renal allograft. The 
number of CD3+ cells was higher in the ABCB5 cell-treated group as compared to the CM-
treated or control group (136,93 ± 50,53 vs. 98,03 ±3 6,62 CD3+ cells; ABCB5-cell treated 
vs. control; p=0,18) In the CM-treated group, the number of CD3+ cells was slightly lower 
than in the control group (92,44 ± 20,4 vs. 98,03 ± 36,62 CD3+ cells, CM-treated vs. control; 
p=0,96). In none of the comparisons statistical significance was reached (Fig.42). No major 





 Fig.41: (A) Quantification of ED1 cells (positivity/µm²) in kidney allograft sections of control 
(n=6), ABCB5+ (n=7) and CM-treated (n=5) groups showed that ABCB5+cell treated group presented 
increased number ED1+ macrophages compared to control and CM-treated animals. Nevertheless, the 
number of ED1+ cells in CM-treated was not lower than in the control group. ED1 staining shows the 
presence of ED1+ macrophages in the kidney allografts of control. The results are displayed as 
boxplots, with the median (middle line), upper and lower quartile (interquartile range, IQR) and 
whiskers (1,5*IQR). Kidney sections of (B), ABCB5 (C) CM-treated and  (D) control animals 98 days 








 Fig:42: (A)Quantification of CD3+ cells in the kidney allograft sections of control (n=6), 
ABCB5+ (n=7) and CM-treated (n=5) animals was performed as described in section 2.9, and showed 
a higher number of CD3+ T cells in ABCB5+ treated animals compared to the other two groups. CM-
treated animals showed slightly lower amount of CD3+ T cells compared to control group, but this 
difference was not statistically significant. The results are displayed as boxplots, with the median 
(middle line), upper and lower quartile (interquartile range, IQR) and whiskers (1,5*IQR). Kidney 






We next assessed the Banff classification scores as described in section 2.11, following the 




The first criterion assessed was the degree of tubulitis (t), scored as follows:   
 
t0= No mononuclear cells in tubules or single focus of tubulitis only (Fig.43a) 
t1= Foci with 1 to 4 mononuclear cells/tubular cross section (Fig.43b) 
t2= Foci with 5 to 10 mononuclear cells/tubular cross section (Fig.43c) 
t3= Foci with >10 mononuclear cells/tubular cross section (Fig.43d) 





 Fig.43: Representative images of the four tubulitis scores (t) in the Banff classification a) t0 
No mononuclear cells in tubules or single focus of tubulitis only; b) t1= Foci with 1 to 4 mononuclear 
cells/tubular cross section; c) t2= Foci with 5 to 10 mononuclear cells/tubular cross section; d) t3= 
Foci with >10 mononuclear cells/tubular cross section. (PAS, 100X) 
 
 
Animals treated with hABCB5+ cells showed the highest tubulitis scores, with one 
animal presenting severe tubulitis. The degree of tubulitis was similar between CM-treated 




Table 2: Tubulitis (t) scores in the allograft sections of KTx control (n=8), 
KTx+ABCB5 (n=7) and KTx+CM (n=5) 98 days after transplantation. 
 
Tubulitis (t) KTx control  KTx+ABCB5  KTx+CM  
None (0) - - - 
Mild (1) 3 (37,5%) 3 (42,86%) 2 (40%) 
Moderate (2) 5 (62,5%) 3 (42,86%) 3 (60%) 
Severe (3) - 1 (14,29%) - 




The second Banff criterion assessed was vasculitis (v). To determine the degree of 
vasculitis, the presence of subendothelial mononuclear cells as well as intimal fibrosis and the 
degree of vascular occlusion are taken into consideration, as follows: 
 
v0—No vasculitis (Fig.44a) 
v1—Mild to moderate intimal vasculitis in at least 1 vessel cross section (Fig.44b) 
v2—Severe intimal vasculitis with at least 25% luminal area lost in at least 1 vessel 
cross section (Fig.44c) 
v3—Transmural vasculitis and/or arterial fibrinoid change and medial smooth muscle 






 Fig.44: Representative images of the four vasculitis scores (v) in the Banff classification.a) 
v0=No vasculitis; b) v1=Mild to moderate intimal vasculitis in at least 1 vessel cross section; c) 
v2=Severe intimal  vasculitis with at least 25% luminal area lost; d) v3=Transmural vasculitis and/or 




In terms of vasculitis, the scores went from no (0) to moderate (2) vasculitis, with no 
animal showing severe signs of vasculitis in any of the groups. As observed for tubulitis, the 
ABCB5 cell-treated group showed the worst outcome, with 28,57% of animals presenting 
moderate vasculitis. The CM-treated and control groups did not reach vasculitis scores above 
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v1, meaning animals presented mild signs of vasculitis. The CM-treated group was 
slightly worse than the control group, but slightly better than the ABCB5 cell-treated group 
(Table 3).  
 
 
Table 3: Vasculitis (v) scores in the allograft sections of KTx control (n=8), KTx+ABCB5 




The third criterion analysed was interstitial fibrosis (ci), which was assessed with 
Masson-Goldner trichrome staining, which specifically demonstrates the presence of 
connective tissue, as follows:  
 
 
ci0—Interstitial fibrosis in up to 5% of cortical area. 
ci1—Interstitial fibrosis in 6 to 25% of cortical area (Fig.45a) 
ci2—Interstitial fibrosis in 26 to 50% of cortical area (Fig.45b)  
ci3—Interstitial fibrosis in >50% of cortical area (Fig.45c) 
 
 
As previously mentioned, interstitial fibrosis is very severe in the Fischer-Lewis 
model, and is the result of chronic cellular and humoral responses against the donor foreign 
MHC molecules. In accordance with this, renal sections of 75% of the animals in the control 
group were classified as ci3. Interstitial fibrosis was even worse in the ABCB5 cell treated 
group where 85,7% of these animals had ci3 scored renal sections. On the other hand, CM 
treatment ameliorates interstitial fibrosis slightly, with 60% of the animals in this group 
presenting a ci3 score (Table 4).  
 
 
Table 4: Interstitial fibrosis (ci) scores in the allograft sections of KTx control (n=8), 
KTx+ABCB5 (n=7) and KTx+CM (n=5) 98 days after transplantation 
 
Vasculitis (v) KTx control KTx+ABCB5 KTx+CM 
None (0) 1 (12,5%) 1 (14,29%) - 
Mild (1) 7 (87,5%) 4 (57,14%) 5 (100%) 
Moderate (2) - 2 (28,57%) - 
Severe (3) - - - 
Interstitial fibrosis (ci) KTx control KTx+ABCB5 KTx+CM 
None (0) - - - 
Mild (1) 1 (12,5%) - 1 (20%) 
Moderate (2) 1 (12,5%) 1 (14%) 1 (20%) 
Severe (3) 6 (75%) 6 (85,7%) 3 (60%) 







The degree of interstitial fibrosis is tightly connected to tubular atrophy (ct), which is 
the next Banff criteria assessed. Tubular atrophy is characterized by a thickening of the 
tubular epithelial cell basement membrane causing a reduction of the tubular diameter that 
leads to its malfunction. The assessment was performed as follows: 
  
ct0—No tubular atrophy. 
ct1—Tubular atrophy involving up to 25% of the area of cortical tubules (Fig.46a). 
ct2—Tubular atrophy involving 26 to 50% of the area of cortical tubules (Fig.46b). 




Fig.45: Representative images of the interstitial 
fibrosis scores (ci) in the Banff classification. a) 
ci1= Interstitial fibrosis in 6 to 25% of cortical 
area; b) ci2= Interstitial fibrosis in 26 to 50% of 
cortical area; c) ci3= Interstitial fibrosis in >50% 
of cortical area. (Masson-Goldner, 100X) 
 
 






The severity of tubular atrophy corresponded to the severity observed for interstitial 
fibrosis, as no animal in any of the groups showed signs of no tubular atrophy. In the control 
group, 62,5% of the animals presented severe tubular atrophy, which was worsened with the 
cell treatment with 71,43% of the animals presenting  a ct3 score. The scores for CM-treated 
animals were milder, with 40% of the animals showing ct3 and 40% of the animals presenting 
mild tubular atrophy (ct1) (Table 5) 
 
 
Table 5: Tubular atrophy (ct) scores in the allograft sections of KTx control (n=8), 
KTx+ABCB5 (n=7) and KTx+CM (n=5) 98 days after transplantation 
Tubular atrophy (ct) KTx control KTx+ABCB5 KTx+CM 
None (0) - - - 
Mild (1) 2 (25%) 1 (14,29%) 2 (40%) 
Moderate (2) 1 (12,5%) 1 (14,29%) 1 (20%) 
Severe (3) 5 (62,5%) 5 (71,43%) 2 (40%) 
Fig.46: Representative images of the tubular 
atrophy (ct) scores in the Banff classification. a) 
ct1=Tubular atrophy involving up to 25% of the 
area of cortical tubules, b) ct2= Tubular atrophy 
involving 26 to 50% of the area of cortical 
tubules, c) ct3= Tubular atrophy involving in 
>50% of the area of cortical tubules. (PAS, 100X) 
 
 





4.1. Long-term renal outcomes of unilateral kidney ischaemia without 
contralateral nephrectomy 
  
 One of the goals of this project was to assess whether the MSC treatment leads to 
amelioration of chronic renal damage after warm ischaemic injury. To that end, we first aimed 
to find the most suitable murine ischaemia-induced AKI model to prompt strong clinical and 
morphological end-points associated to progressive CKD to subsequently determine 
therapeutic efficacy of MSC. The vast majority of murine AKI models are based on renal 
ischaemia. Depending on the duration of renal ischaemia, these models can inflict severe 
kidney function impairment and hence are valuable tools to study the mechanisms underlying 
the initial injury
135
.However, long-term studies showing progression to chronic kidney disease 
after an ischaemic insult are scarce and the observation time in most cases is too short to draw 
reliable conclusions
45
.The two models of ischaemia- induced AKI that have been studied 
mostly in this context are: induction of renal ischaemia followed by nephrectomy of the 
contralateral kidney and similarly, without removal of the non-ischaemic kidney. The latter 
model seems more suitable as it allows longer ischaemia times without increased mortality 
rates.
44
 Therefore, for our first approach we decided to implement the model without 
contralateral nephrectomy after ischaemic injury in order to assess whether indeed signs of 
progressive CKD were observed in the long-term. However, the main down-side is the 
difficulty to monitor the function of the post-ischaemic kidney in the acute phase when a fully 
functional kidney is also present. Renal function of the post-ischaemic kidney is mostly 
studied at later time-points when the non-ischaemic contralateral kidney is removed. 
 
Additionally, it is important to remark that most long-term studies to assess 
progression to CKD after ischaemic injury base their conclusions regarding kidney function 
deterioration solely on the assessment of proteinuria
136,137
. Proteinuria has been classically 
regarded as a reliable parameter to assess progressive kidney function deterioration. However, 
a recent epidemiological study suggests that the combination of GFR and proteinuria are the 
best predictors to assess progression to CKD
138
. Consequently, we implemented both the 
assessment of proteinuria and GFR in our study. The latter was performed by a minimally 
invasive technique that measures the clearance of FITC-S transcutaneously. Since FITC-S is 
exclusively cleared by the kidney, it is an optimal marker for the estimation of GFR
126
.   
 
When ischaemia-reperfusion injury was induced in non-uninephrectomized animals, 
kidney function parameters remained within the non-pathologic range, until the contralateral 
non-ischaemic kidney was removed. This underscores the difficulties in measuring renal 
function parameters of the ischaemic kidney in the acute phase. Proteinuria was the only 
exception, being mildly increased (≥22mg/24h) at day 150 when the non-ischaemic kidney 
was still present. Hence, even though FITC-S clearance was not impaired, proteinuria was 
present in these animals. This phenomenon has been reported in epidemiologic studies where 
25% of patients with proteinuria also presented normal GFR
138
. As a matter of fact, the 
presence of proteinuria in absence of impaired GFR may identify  a subpopulation of patients 




Interestingly, in this model the right non-ischaemic kidney was significantly increased 
in size compared to the right kidney of control animals that were not subjected to renal 
ischaemia. In contrast, the ischaemic kidney was small and showed an irregular and a wrinkly 
surface possibly due to accumulation of fibrotic tissue. A compensatory growth of the
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contralateral non-ischaemic kidney is therefore expected and known to occur after 
kidney injury. Although the underlying mechanisms are not completely elucidated, it is 
believed that loss of nephron mass results in the local production of several growth factors, 
e.g. Insulin-like growth factor (IGF), fibroblast growth factor (FGF), vascular epithelial 
growth factor (VEGF), epidermal growth factor (EGF), nerve growth factor (NGF) and 
hepatocyte growth factor (HGF), which act in an autocrine or paracrine manner mostly 






Another compelling finding was the presence of different sized cysts in half of the 
animals that were subjected to AKI. The presence of solitary cysts located in the renal cortex 
(cysts stage I) in asymptomatic individuals is considered benign
142
. However, in individuals 
with kidney function impairment a simple renal cyst is associated with poorer outcome and is 
considered a feature toward progression to chronic kidney disease
143
. Loss of functional tissue 
may trigger residual nephrons to undergo epithelial hypertrophy and hyperplasia, leading to 
increased size of tubular structures and thus cyst formation. Also fibrosis facilitates cyst 





 Progressive chronic kidney disease is associated with interstitial fibrosis (IF). IF is the 
result of persistent stimuli that causes sustained production of growth factors, proteolytic 
enzymes, angiogenic factors and fibrogenic cytokines that promote extracellular matrix 
(ECM) deposition between tubules and peritubular capillaries, eventually leading to the 
disruption of the normal tissue architecture
145
.The degree of IF was quantified in the post-
ischaemic kidneys using a technique in which the positively stained ECM components were 
identified and quantified as percentage of the whole surface area of a particular renal section. 
This technique let us put aside the use of IF scores, which have the disadvantage of being less 
reproducible and objective, as usually the results vary depending on the observer
146
. As to be 
expected, the percentage of IF presented in the cortex was significantly higher than in the 
control group. However, the degree of IF observed in the post-ischaemic kidneys was 
relatively mild, with a maximum value of 0,676% out of total cortex.  A recent study has 
shown that IF is an imperfect predictor of chronic kidney disease in some patients, 
emphasizing the superiority of reliable kidney function parameters, like eGFR
147
. Thus, the 
model employed in this approach leads to clinically relevant endpoints, e.g. renal function 
deterioration, interstitial inflammation and cyst formation, making it a good candidate model 
for interventional studies. 
 
 
 4.2. Role of the kidney mass at the time of ischaemic injury in the long-term renal 
outcomes 
 
 Our second approach was based on the existing discrepancy in scientific literature 
regarding the role of the renal mass at the time of ischaemic injury in animal models. Some 
authors suggest that unilateral kidney ischaemia with contralateral nephrectomy at the time of 
injury leads to a worse long-term outcome
136,148
; whereas others claim that unilateral 
ischaemia without contralateral nephrectomy worsens outcome, as the presence of an 
undamaged contralateral kidney might have a deleterious effect rather than a protective one in 
the long-term
49,149
.Thus, in order to shed light upon this topic we aimed to compare the long-
term functional and morphological outcomes between the aforementioned models.  
 
Kidney function was assessed in the early phase of the ischaemic injury (1-3 days after 
AKI induction) to understand how the initial response to injury might affect the long-term
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 outcomes. As expected, the initial ischaemic injury led to profound kidney function 
impairment in the nephrectomised animals 1 day after AKI-induction. Function remained 
impaired at day 3 after AKI and returned to baseline values after 7 days. On the other hand, 
non-uninephrectomised animals showed kidney function parameters values within the 
physiological range at all the early time points, meaning that the non-ischaemic kidney was 
able to compensate the injury to the contralateral kidney and thus, the overall kidney function 
was preserved. However, despite this initial impact on kidney function, uninephrectomised 
animals were able to recover and showed no signs of functional deterioration at day 177 after 
AKI. In contrast, non-uninephrectomised animals presented signs of renal impairment once 
the non-ischaemic kidney was removed.  
 
Histopathological findings are in agreement with functional assessment as 
uninephrectomised animals presented less ED1+ macrophage infiltration and thus, a lesser 
degree of interstitial fibrosis in the cortex compared to non-uninephrectomised animals when 
kidney sections were analysed 180 days after the initial ischaemic injury. Interestingly, the 
lesion pattern found was different among the two groups. In the uninephrectomised animals a 
higher number of greatly dilated tubules was found, mostly in the inner cortex; whereas in the 
non-uninephrectomised group tubular dilation to such extent was not observed and fibrotic 
tissue accompanied by atrophic tubules were found in the very outer cortex. This higher 
extent of tubular dilation in uninephrectomised animals could be explained by the fact that 
initial injury lays on a single kidney and tubular dilation is found during acute tubular 
necrosis, where tubular epithelial cells undergo apoptosis after the ischaemic injury, detach 




In the light of our results, it can be inferred that unilateral ischaemia without 
contralateral nephrectomy at the time of injury leads to a more severe long-term functional 
and morphological kidney deterioration. The reasons for this are not fully known, although it 




The question that needs to be discussed is the role of the contralateral kidney in 
ischaemia induced AKI. In the following I will discuss the studies that provided evidence that 
the presence of the contralateral kidney is not beneficial for renal function recovery after an 
ischaemic insult, and therefore unilateral nephrectomy might ameliorate long term renal 
function decline. 
 
It is believed that presence of a contralateral kidney intensifies early post-ischaemic 
renal vasoconstriction, thus increasing renal hypoperfusion
149
. Therefore, the potential 
protective role of uninephrectomy (uNx) is a phenomenon that has been extensively studied. 
It has been suggested that uNx leads to a reduction of apoptotic cells and DNA fragmentation 
and enhanced proliferation of tubular cells leading to tissue repair in the remnant kidney
153
. 
This might be caused by an increased intrarenal expression of several growth factors such as 
EGF, IGF and HGF in the post-ischaemic kidney, favouring tissue regeneration. Also 
thromboxane A₂ (TxA₂) synthesis is decreased in the post-ischaemic kidney, which may 
cause less vasoconstriction, less secondary ischaemia und thus less apoptosis
154
. Not only 
TxA2, but also the prominent vasoconstrictor endothelin-1 (ET-1) is decreased in uNx animals 
compared to non uNx. Compatible with this, it has been shown that administration of ET-1 
receptor antagonists can amelioration of GFR decline and tubular injury
155
.The protective role 
of uNx in ischaemic injury has also been demonstrated in dynamic contrast enhanced MRI 
(DCE-MRI) studies, in which it was found that uNx enhances perfusion to the inner medulla 
in the remnant kidney
152
.Gene expression profiling studies in AKI-induced 
uninephrectomised animals have shown that uNx mostly downregulates genes involved in
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 would healing, ECM and myofibroblast differentiation
152,156
.These gene expression 
results correlate with our histopathology findings, as a much milder degree of interstitial 
fibrosis was found in the post-ischaemic kidneys of uninephrectomised animals.  
 
Another interesting hypothesis is that the ischaemic insult to one kidney leads to injury 
to the non-ischaemic kidney because of kidney cross-talk. This is reflected by a change in 
macrophage population (M1)
151,157
, increased pro-inflammatory cytokines such as TNF-α 
which was much more prevalent in tubular cells of ischaemic kidneys, in contrast to the non-
ischaemic kidneys, where higher TNF-α expression is observed in glomerular cells, 




In the present study, the non-ischaemic kidneys and the ischaemic kidneys were 
collected for histopathology assessment 170 or 180 days after ischaemic induction, 
respectively. At these time points, ED1+ macrophages were not increased in the non-
ischaemic kidneys, and no signs of morphological alterations or tissue fibrosis were observed. 
However, even though no histopathological changes were observed in the non-ischaemic 
kidneys, the finding that the long-term injury is more severe when a functional kidney is 
present, warrants further studies to address if this is attributable to kidney cross-talk.  
 
 
4.3. Role of human adipose-derived MSC (hASC) in the amelioration of chronic renal 
damage caused by warm ischaemia 
 
In recent years, adipose-derived MSC (ASC) have gained relevance over bone 
marrow-derived MSC (BM-MSC) in preclinical studies because they are easier to obtain and 
in larger quantities using less invasive techniques. For instance, it has been reported that from 
lipoaspirates 2% of nucleated cells can be recovered as MSC in comparison to the 0,002% 
obtained from bone marrow
159
. Furthermore, several in vitro studies have shown that ASC 
present higher immunomodulatory capacities compared to BM-MSC
160,161
. In the light of the 
results of the previous experiments in the AKI models, hASC, treatment was implemented in 
the model leading to more long-term kidney function deterioration.  
 
When our experiments were being planned, one of the main setbacks was the lack of 
consensus in literature concerning the most suitable administration route and cell dose to 
achieve the most favourable outcome, as it would depend on several factors like species or 
target organ(s). In our study, hASC were injected intravenously, representing the most 
commonly used administration route in clinical practise. Although in one study intra-arterial 
administration in the aorta has been reported to be more efficient than intravenous injection, 
as it ensures that the cells reach the kidney
162
; intra-aortic injection was not considered in our 
study because of the need to subject the animals to a second surgical procedure within a short 
period of time. Even though intravenous injection may lead to hASC entrapment into the lung 
capillary system
163
, a large body of evidence suggests that the therapeutic efficacy of MSC is 
independent of cell engraftment into the target organ. In fact, secretion of paracrine factors is 
recognized as the primary mechanism used by MSC to promote regeneration of the injured 
tissue
111,164
. Similar to the administration route, also the amount of stem cells that should be 
injected is ambiguously discussed, albeit that most rodent-based preclinical models use a cell 
concentration that ranges from  to  cells
165
. The assessment of therapeutic 
efficacy of MSC in AKI murine models has been widely addressed in preclinical studies that 
focus mostly in the acute phase of the injury and use autologous or allogeneic cells as a 
source for treatment
166
. In this study, however, human ASC were incorporated in a rat model 
Discussion  - 78 - 
 
 
of ischaemia-induced AKI to assess the long-term outcomes. Human MSC have been 
reported to be hypoimmunogenic or ‘immune privileged’, as they display intermediate levels 
of HLA class I, no basal expression of HLA class II and no expression of the costimulatory 
molecules CD80, CD86 and CD40. However, in recent studies the hypoimmunogenic status 
of MSC is being questioned
167
, as it was shown that MHC mismatched MSC are able to 
induce both cell-mediated and humoral immune responses in vivo
168,169
 . In our study, after 
cell injection all animals were under observation for at least 2 hours, as it has been reported 
that intravenous cell injection might present side effects ranging from death by lung emboli 
formation to fever or nausea
170
. No incidences were reported after IV injection, it was well-
tolerated and animals showed no signs of respiratory distress or lethargy caused by fever. 
Nevertheless, this lack of clinical signs does not necessarily correlate with immune responses 
or rejection of MSC, so in future studies it would be interesting to assess T cell-mediated and 
humoral responses through ex-vivo assays and see whether there is a correlation with the 
outcome of the treatment.  
 
It has been shown that neither human nor murine MSC are able to induce any 
immunoregulatory action per se unless they have been previously stimulated by IFN-γ. In the 
presence of an inflammatory environment (high levels of IFN-γ and TNF-α) MSC are 
activated and adopt an immunosuppressive phenotype (MSC2), secreting soluble inhibitory 
factors. It seems that IFN-γ induces the expression of IDO-1
171
, the first and rate-limiting 
enzyme of tryptophan degradation through the kynurenine pathway. Suppression is mostly 
explained by deprivation of tryptophan for T lymphocyte proliferation
172
 but can also be 
explained by the cytotoxic action of kynurenines on T lymphocytes and NK cells
173
. 
Similarly, induction of iNOS in murine MSC by IFN-γ and TNF-α is a prerequisite for their 
immune suppressive properties. Other immune-inhibitory molecules such as PGE2 are 
produced by both human and rodent MSC
174
.Even though human MSC cannot be activated by 
murine IFN-γ, human MSC have shown cross-species reactivity with murine TNF-α 
175
,which 
may explain the success of human MSC in a number of murine models.
85
 In the absence of an 
inflammatory milieu (low levels of IFN-γ and TNF-α) MSC adopt a pro-inflammatory 
phenotype (MSC1)
176
.In this study, cell treatment was implemented at day 14 after AKI 
induction. Based on gene expression profiling studies it is likely that at his time point 
sufficient pro-inflammatory cytokines (e.g.TNF-α) are present in the renal environment that 
would allow hASC to display a MSC2 immunosuppressive behaviour
177
. Indeed, one of the 
main findings regarding hASC treatment in this ischaemia-induced AKI model was the highly 
significant decrease in ED1+ macrophages in the post-ischaemic kidneys. Macrophages 
constitute the first wave of inflammatory cells that migrate to the kidney during ischaemia-
reperfusion injury, and thus, they play an important role in activation and continuation of the 
inflammatory response. They are also involved in tissue fibrosis, as once macrophages are 
activated by IFN-γ and TNF-α, they subsequently produce TGF-β1, which acts as a feedback 
mechanism in inflammation resolution, but also triggers fibroblast activation and 




The mechanism by which hASC might have been able to reduce ED1+ macrophages 
in the post-ischaemic kidneys is in agreement with what has been previously stated. hASC 
injection in a pro-inflammatory environment where TNF-α is present, adopt an 
immunosuppressive phenotype. This might lead to PGE2 production by hASC, which can 
polarize monocytes to M2 macrophages, a subtype of macrophages which produces anti-
inflammatory cytokines and shows higher phagocytic activity. This mechanism of action is 
supported by an in vitro study by Manferdini et al.,
86
where it was found that when M1 
macrophages from synovium of osteoarthritis patients were co-cultured with hASC, M1 
markers like IL-1β, IL-6, MIP1α/CCL3 were decreased in indirect and direct co-culture
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conditions. Furthermore, M2 markers IL-10, CD163 and CD206, were enhanced, meaning 
that hASC were able to cause polarization to M2 macrophages. In addition, it was also found 
that PGE2 was upregulated in the co-cultures and that blocking PGE2 with an antagonist led 
to no decrease in TNF-α, IL-6 and no increase in IL-10, CD163 and CD206, suggesting that 
PGE2 presents a specific role in this mechanism. This polarization to M2 macrophages 
mediated by PGE2 is produced by cell-to-cell contact or when PGE2 binds to the EP2 and 




It must be noted that ED1 is a monoclonal antibody directed against the rat protein 
CD68, which is a pan marker of macrophages, meaning that it is not able to distinguish 
between M1 and M2 macrophages
180
. Nevertheless, the fact that hASC treatment was able to 
reduce the degree of kidney fibrosis in the post-ischaemic kidneys supports the idea that cell 
treatment was able to switch macrophage activity to an anti-inflammatory state.  
 
On the other hand, one of the pitfalls of this study is the administration time chosen. 
Even though it has been shown that 14 days after AKI induction there is still ongoing 
inflammation, it is a rather late time point to implement a treatment and a quite improbable 
scenario in clinical practise. This time point was initially chosen because hASC treatment was 
conceived to boost repair, which takes place later in time, toward adaptive mechanisms, and 
thus help halt the progression to CKD
38
. Nevertheless, as it has been stated, a highly pro-
inflammatory environment confers MSC the immunomodulatory phenotype, and therefore, in 
future studies, treatment should be implemented in the early phases of AKI induction. 
 
 
4.4. Role of human ABCB5+ cells and its derived CM on the amelioration of 
chronic renal damage after cold ischaemia and minor MHC disparity 
 
 In contrast to what occurs in humans
181
, our murine warm ischaemia approaches led to 
a rather mild degree of kidney function impairment and overall kidney fibrosis in the long-
run, even when the initial ischaemic insult was severe. Therefore, we aimed to find a 
chronicity model resulting in strong clinical and morphological end-points and wondered 
whether this could be achieved by implementing cold ischaemia and minor MHC disparity. 
Thus, in this approach a Fischer-Lewis allograft rejection model, with 8 hours of cold 
ischaemia was employed. To investigate whether cell therapy could mitigate the functional 
and histopathological features found in this model, human stromal cells expressing the ATP-
binding cassette B member 5 P-glycoprotein (ABCB5+ cells) were implemented as 
intervention strategy. P-glycoproteins and members of the ABC superfamily are cell 
membrane proteins that use an ATP-dependent pump to efflux different types of xenobiotics 
out of the cell and mediate drug resistance in mammalian cancers, as well as physiologic 
transport, differentiation and survival in non-cancerous cells. ABCB5 was first described by 
Frank et al. on the CD133-positive progenitor cell subpopulation in human epidermal 
melanocytes in 2003
182
, and it has also been found in human placenta
183
 as well as in corneal 
limbal stem cells thereafter
184
. Interestingly, ABCB5 has been shown to identify a 
phenotypically distinct subpopulation of dermal cells that can exert immunomodulatory 
actions
185
, and since more than 90% of ABCB5+ cells fulfil the criteria for MSC (no 
expression of CD34, CD31 and CD45 and positive expression of CD29, CD44, CD49e, 
CD73, CD105 and CD166)
84
, they are considered a subtype of MSC with similar therapeutic 
potential as the adipose-derived or bone marrow-derived counterparts. Furthermore, ABCB5+ 
cells have been used with promising results in a murine heart allograft rejection model
185
 and 
are being tested in a number of clinical trials (ie: acute on chronic liver failure, epidermolysis 
bullosa, chronic venous ulcers
186-188
).  
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Additionally, we also aimed to assess whether cell-free therapy in the form of 
ABCB5-derived conditioned media showed better outcomes compared to the cell counterpart. 
MSC-CM content has been reported to differ greatly depending on the cell type used as a 
source and the culture conditions
189
, but several proteomic analyses have revealed that 
angiogenic factors (angiogenin, angiopoietin, VEGF), chemokines (CX3CL1, CCL1, CCL2, 
CCL5…), cytokines (IL-1α, IL-1β, IL-10, TNF- α, IFN-γ, M-CSF, TSG-6…), growth factors 
(HGF, EGF, PIGF, PDGF, BMP-7…) and other proteins (leptin, adiponectin…) are general 
components of MSC-CM
190
. In addition, MSC-CM is reported to contain extracellular 
vesicles which carry mRNAs involved in transcription, immune regulation, cell cycle 
regulation, angiogenesis, actin cytoskeleton regulation and extracellular matrix remodelling 
191,192
. Furthermore, several clinical trials using MSC-CM are being conducted for a number 




Before assessing the therapeutic efficacy of the treatments in a transplantation model it 
is important to elucidate how much of the functional and morphological changes observed are 
due non-allogeneic factors like ischaemia-reperfusion injury and cold preservation and how 
these changes vary when allogeneic factors are also involved. For that reason, syngeneic 
transplantation data is important to assess the changes caused solely by IRI and cold 
preservation. In a study by Gottmann et al., syngeneic transplantation in Lewis rats (Lew-
Lew) was performed after 24 hours of cold preservation, and the outcome of the procedure 
was assessed for 24 weeks
196
. Throughout the experimental time it was observed that p-crea 
values remained stable and within the physiologic range, and that a slight proteinuria was 
developed in the beginning, but did not progress over time. As for the Banff classification, the 
totality of the animals showed no signs of interstitial infiltration (ci0), tubular atrophy (ct0), 
glomerulosclerosis (cg0) or vasculopathy (v0). We therefore used in our study an allogeneic 
transplantation model with minor MHC differences, and implemented a cold ischaemia time 
of 8 hours. This resulted in severe renal function impairment at all time points after 
transplantation accompanied by moderate tubulitis, mild vasculitis, severe interstitial fibrosis 
and severe tubular atrophy. Hence, syngeneic transplantation after 24 h of ischaemia leads to 
a milder outcome compared to an allogeneic transplantation model with shorter cold 
ischaemia time (8h). This underscores the role of the ongoing allogeneic response on top of 
the IRI. The functional and morphological findings in the Fischer-Lewis model used in our 




Like for the AKI experiments, transcutaneous assessment of kidney function was 
implemented in this model by measuring FITC-S clearance. It is worth to mention that this 
technique was quite troublesome in animals with severe kidney function deterioration, as the 
optimal FITC-S dosage had to be adjusted various times in order to maintain in a fluorescence 
intensity range that allows capturing of the maximum fluorescence intensity during the 
flooding phase. Yet the peak needs to be sufficiently high for obtaining a valid elimination 
curve. Additionally, it must be noted that in this section of the study we faced great peri-
operative mortality due to the severity of the surgical procedure. As a consequence, group 
sizes were dramatically reduced, hence the lack of statistical significance observed for the 
clinical and histopathological parameters among the three experimental groups.  
 
  Similar as reported for the AKI experiments, the time of ABCB5 cell administration 
plays a crucial role in transplantation outcome. It has been reported that MSC administration 
before renal transplantation leads to MSC engraftment into secondary lymphoid organs, 
favouring graft survival
198
. In contrast, a single post-transplant injection has been shown to 
induce MSC migration directly into the graft, resulting in neutrophil infiltration, complement 
deposition and acute kidney injury, both in animal and human studies
199
. The first study with
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 the use of ABCB5+ cells in vivo
185
was a heterotopic allogeneic heart transplantation model in 
C57BL/6 mice. It was found that when recipient-derived ABCB5+ cells were injected 7 days 
before transplantation, no significant graft survival was observed. Similarly, donor- BALB/c 
derived ABCB5+ injection at the same time point led to modest prolongation of graft 
survival. However, when a third-party C3H/HeJ heart was transplanted into a C57BL/6 mouse 
and BALB/c-derived ABCB5+ cells were injected, survival of the graft was greatly increased, 
suggesting that the enhancement of survival mediated by ABCB5+ cells required previous 
allogeneic stimulation. Taking this into account, we considered one day before kidney 
transplantation as the optimal time point for cell administration in our study. Because it also 
was reported that survival of exogenously administered MSC decays after 24 hours
200
we 
performed a second cell injection 17 days after kidney transplantation. This time point was 
chosen because the animals underwent contralateral nephrectomy 10 days after kidney 
transplantation, allowing them to recover from the surgical procedure before cell injection.  
 
As it has been previously mentioned, the Fischer-Lewis model of chronic allograft 
rejection leads mostly to histopathology lesions associated with T-cell mediated rejection. 
Therefore, hABCB5+ treatment was aimed to decrease the main histopathologic features 
associated with T-cell mediated rejection, namely tubulitis, interstitial fibrosis and 
endarteritis. ABCB5+ cells have been shown to exert immunosuppressive effects on effector 
T cells and to induce the production of CD4+CD25+Foxp3+ Tregs via PD-1/PD-L1 signaling 
interactions in vivo and in vitro
185
. PD-1 is a negative regulator of T cell activity and when it 
binds to either of its two ligands (PD-L1 and PD-L2) it inhibits kinase signalling pathways 
that lead to CD4+T cell activation
201
. Our findings, however, suggest that hABCB5+ were not 
only unable to suppress T mediated rejection, but rather show exacerbation in histological 
findings for T-cell mediated rejection, albeit that this was not significant. The reasons for this 
are still elusive. Notwithstanding that in some preclinical transplantation studies cell pre-
treatment was associated with better outcome
198
, in a safety assessment study using hACB5+ 
in mice it was found that after IV injection cells were mostly detectable in the lungs
122
, and 
not in the lymphoid tissue. Moreover, as discussed earlier, the injection of MSC in the 
absence of a pro-inflammatory environment might lead to a MSC switch toward a pro-
inflammatory phenotype (MSC1) and as a consequence, to enhancement of T cell 
responses
176
. Most importantly, MSC have been shown to express and secrete PD-L1 and PD-
L2 only when exposed to IFN-γ and TNF-α
202
. Hence pre-treatment bears the risk of MSC 
switching if at the time of injection no inflammation is present.  
   
On the other hand, ABCB5+ cells role on macrophage activity is associated to their 
ability to trigger the switch from M1 to M2 macrophages trough the secretion of IL-1 receptor 
antagonist (IL1-RA)
128
.As observed for T cells, kidney allograft sections of hABCB5+ treated 
animals presented a trend toward increased infiltration of ED1+ macrophages compared to 
CM-treated or the control group. Macrophages upregulate mediators involved in 
microvascular damage, leucocyte recruitment and induction of donor-specific cytotoxic 
responses
203
, and it has been reported that 38-60% of infiltrating leukocytes in the rejecting 
organs are macrophages, being their presence is associated with poorer outcome
204
. In the 
presence of a pro-inflammatory environment, MSC have been shown to increase their 
expression of IL-1RA
87
, which in our study, could mean that after the second injection, 17 
days after KTx, the conditions were favourable to induce macrophage polarization to M2 
phenotype. However, prolonged activation of M2 macrophages may also lead to activation of 
resident fibroblasts through continuous activation of TGFβ and growth factors, thus 
promoting fibrosis
203
. As a matter of fact, in studies using biopsies from patients undergoing 
chronic allograft rejection, M2 macrophages have been found to be the predominant 
macrophage population
205
, and this finding has been linked to the development of a higher
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 extent of interstitial fibrosis and tubular atrophy
206
. Therefore, even though in our 
study ED1staining is not able to differentiate between M1 and M2 macrophages, the higher 
interstitial fibrosis and tubular atrophy scores in the cell-treated group could be explained by a 
macrophage shift toward M2 phenotype by ABCB5+ cells, that promoted fibrosis in the long-
term. This needs to be addressed in future studies.  
 
Although not statistically significant, treatment with conditioned media showed a 
trend towards milder vasculitis, interstitial fibrosis and tubular atrophy Banff scores compared 
to control and cell-treated group. Likewise there was a trend for a better FITC-S clearance at 
day 98 after transplantation in the CM treated group. In this context, ABCB5+-derived CM 
might have helped reduce vasculitis through enhancement of pro-angiogenic mechanisms, as 
one of the main properties attributed to MSC-CM is their angiogenesis potential. In a study by 
Estrada et al.
207
 it was found that MSC-CM can induce angiogenesis via cysteine-rich protein 
61 (Cyr61), which was found to induce neovascularization in vivo. This angiogenic effect has 
also been reported to take place through the release of exosomes by MSC, which are able to 
deliver miRNA to endothelial cells, subsequently upregulating angiogenic factors
208
. As 
previously mentioned, the treatment with ABCB5+ derived CM lead to a milder interstitial 
fibrosis and tubular atrophy score, which can be attributed to the reported anti-fibrotic 
potential of CM. MSC-CM has been shown to attenuate fibrosis in unilateral ureteral 
obstruction (UUO) models by reducing TGF-β1, α-SMA, TNF-α and collagen I expression
209
. 
Furthermore, MSC-CM treatment helped reduce ECM deposition, inflammatory cell 
infiltration and inhibited the TLR4/NF-κB signalling pathway
210
, whose is activation is 
reported to enhance interstitial fibrosis
211
. Nevertheless, functional and morphological 
differences between CM-treated and control group were very subtle. This could be partially 
explained by the fact that CM was obtained from unstimulated cells. As a matter of fact, it has 
been reported that hypoxic preconditioning of MSC enhances their angiogenic and 
cytoprotective potential
212
. Hypoxia induces MSC to express higher levels of HIF-1α, and the 
growth factors GDNF (glial cell line-derived neurotrophic factor), BDNF (brain-derived 
neurotrophic factor), VEGF, Ang-1, SDF-1 (stromal cell-derived factor 1) and its receptor 
CXCR4, as well as increased expression of EPO (erythropoietin) and its receptor EPOR
213
. 
This pro-angiogenic enhancement was further assayed in vivo in an acute myocardial 
infarction model, where an improvement was observed due to increased vascularization
214
. 
Thus, for future studies it might be interesting to address the outcomes after implementing the 




4.5. Conclusions  
 
To sum up our study suggests that: 
 
1. Murine models that implement 60 minutes of warm kidney ischaemia without 
contralateral nephrectomy at the time of injury are better candidates for 
interventional studies on progression of CKD compared to kidney ischemia models 
with contralateral nephrectomy. However, in long term neither of these models 
shows severe renal function impairment. 
2. In contrast, long-term observations in the Fischer-Lewis model of kidney allograft 
rejection with 8 hours of cold ischaemia are indicating that this model is more 
superior for interventional studies as it leads to severe renal function impairment 
with typical histopathological features of chronic rejection.  
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3. hASC treatment in the AKI model without contralateral nephrectomy leads to a 
significant decrease in ED1+ macrophages in sections of post-ischaemic kidneys. 
Furthermore, a decrease in p-crea is observed once the contralateral kidney is 
removed, compared to the AKI-induced vehicle treated group. 
4. CM treatment might be a better candidate compared to MSC treatment in models 
of allograft rejection, although this needs to be further elucidated. 
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5. Summary  
 
Several epidemiological studies have shown that AKI is a risk factor for progression to 
CKD. IRI is one of the main causes of AKI, and for that reason, murine models of AKI are 
mostly based on renal ischaemia, although in most cases the observation time of these studies 
is too short to draw reliable conclusions regarding the long-term outcomes. This study 
provides a description of the long-term renal outcomes of murine models of warm ischaemia 
and addresses the current discrepancies in scientific literature concerning the role of the renal 
mass at the time of ischaemic injury. Furthermore, the transcutaneous evaluation of kidney 
function was implemented measuring FITC-S clearance, which was a very useful, non-
invasive and sensible technique, particularly in animals with mild to moderate kidney 
function impairment, but proved troublesome in animals with severe kidney function 
deterioration.  
 
In the context of warm ischaemia models, unilateral ischaemia without contralateral 
nephrectomy at the time of injury led to long-term kidney function deterioration, once the 
non-ischaemic kidney was removed. Additionally, histopathological analysis revealed cyst 
formation, increased number of ED1+ macrophages and a higher extent of interstitial fibrosis 
compared to the animals nephrectomised right after ischaemic injury. Thus, this model makes 
a good candidate for interventional studies. 
 
Since AKI patients have to rely in supportive care and renal replacement therapy, new 
therapeutic modalities are greatly needed. Thus, MSC as well as MSC conditioned media 
therapies have become an interesting choice because of their many attributed properties. 
Therefore, in this study the treatment with hASC was implemented in the aforementioned 
warm ischaemia model, with a single injection 14 days after injury. The main finding was a 
strong reduction of ED1+ macrophages in the post-ischaemic kidneys of the cell treated 
animals vs. vehicle-treated. This might be explained by the notion that in a pro-inflammatory 
milieu, hASC adopt an immunosuppressive phenotype that might lead to PGE2 production by 
hASC, causing monocyte polarization to M2 macrophages. 
 
Cold ischaemia and minor MHC disparity were implemented in order to increase the 
severity of the model and achieve strong clinical and morphological end-points. This was 
indeed attained using a Fischer-Lewis kidney transplantation model with 8 hours of cold 
ischaemia. Thereafter, the treatment with ABCB5+ cells and its derived CM was 
implemented, one day before and seventeen days after KTx. Neither of the treatments was 
able to significantly ameliorate any kidney function parameter, although a trend toward 
worsened kidney function was observed in the cell-treated group. Likewise, the number of 
ED1+ macrophages and CD3+ T cells in the kidney grafts was not significantly reduced by 
either treatment. This lack of inhibition might be explained by the cell pre-treatment, as it has 
been reported that when no inflammation is present MSC can switch to a pro-inflammatory 
phenotype. As for the Banff classification scores, this model leads to lesions mostly 
associated mostly to T-cell mediated rejection, namely tubulitis, vasculitis, tubular atrophy 
and interstitial fibrosis. In this context, cell-treated animals presented the worst scores in all 
four criteria and no great difference between the control group and CM-treated group were 
observed, besides a trend toward improved vasculitis and interstitial fibrosis in the CM-
treated group. This might be attributed to the angiogenic and anti-fibrotic potential of MSC 
secretome components.  
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